As filed with the Securities and Exchange Commission on August 15, 2006
Registration No. 333-134814
================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
AMENDMENT No. 1
To
FORM S-3
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
DUSA PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Its Charter)
NEW JERSEY 22-3103129
(State or Other Jurisdiction (I.R.S. Employer
of Incorporation or Organization) Identification No.)
25 UPTON DRIVE
WILMINGTON, MASSACHUSETTS 01887
(978) 657-7500
(Address, Including Zip Code, and Telephone Number,
Including Area Code of Principal Executive Offices)
DR. D. GEOFFREY SHULMAN, CHAIRMAN OF THE BOARD AND CEO
DUSA PHARMACEUTICALS, INC.
25 UPTON DRIVE
WILMINGTON, MASSACHUSETTS 01887
(978) 657-7500
(Address, Including Zip Code, and Telephone Number,
Including Area Code of Agent For Service)
COPIES TO:
NANETTE W. MANTELL, ESQ.
REED SMITH LLP
136 MAIN STREET - SUITE 250
PRINCETON, NEW JERSEY 08543-7839
(609) 987-0050
Approximate date of commencement of proposed sale to the public: From time to
time after the effective date of this Registration Statement.
If the only securities being registered on this Form are being offered pursuant
to dividend or interest reinvestment plans, please check the following box. [ ]
If any of the securities being registered on this Form are to be offered on a
delayed or continuous basis pursuant to Rule 415 under the Securities Act of
1933, other than securities offered only in connection with dividend or interest
reinvestment plans, check the following box. [X]
If this Form is filed to register additional securities for an offering pursuant
to Rule 462(b) under the Securities Act, please check the following box and list
the Securities Act registration statement number of the earlier effective
registration statement for the same offering. [ ]
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under
the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement
for the same offering. [ ]
If this Form is a Registration Statement pursuant to General Instruction I.D. or
a post-effective amendment thereto that shall become effective upon filing with
the Commission pursuant to Rule 462(e) under the Securities Act, check the
following box. [ ]
If this Form is a post-effective amendment to a Registration Statement filed
pursuant to General Instruction I.D. to register additional securities or
classes of securities pursuant to Rule 413(b) under the Securities Act, check
the following box. [ ]
THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR DATES
AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL FILE
A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION STATEMENT
SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(A) OF THE
SECURITIES ACT OF 1933 OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME
EFFECTIVE ON SUCH DATE AS THE COMMISSION, ACTING PURSUANT TO SAID SECTION 8(A),
MAY DETERMINE.
================================================================================
The information in this prospectus is not complete and may be changed. We may
not sell these securities until the registration statement filed with the
Securities and Exchange Commission is effective. This prospectus is not an offer
to sell these securities and it is not soliciting an offer to buy these
securities in any state where the offer or sale is not permitted.
PROSPECTUS
Subject to Completion, Dated August 15, 2006
2,396,245 SHARES
DUSA PHARMACEUTICALS, INC.
COMMON STOCK
This prospectus relates to the resale of 2,396,245 shares of our common stock,
no par value per share, by the former shareholders and optionholders of Sirius
Laboratories, Inc. set forth in this prospectus under the section entitled
"Selling Shareholders" on page 14. Such shares of common stock were issued to
such persons pursuant to a merger agreement dated as of December 30, 2005, as
amended on February 6, 2006, by and among DUSA, Sirius and certain shareholders
of Sirius.
We will not receive any proceeds from the sale of the shares hereunder.
The Selling Shareholders identified in this prospectus, or their pledgees,
assignees and successors-in-interest, may offer the shares from time to time
through public or private transactions at prevailing market prices, or at
privately negotiated prices.
INVESTING IN THE COMMON STOCK INVOLVES A HIGH DEGREE OF RISK.
SEE RISK FACTORS BEGINNING ON PAGE 1.
Our common stock is traded on The NASDAQ Global Market under the symbol
"DUSA."
The last reported sale price of our common stock on NASDAQ on August 14, 2006
was $4.12 per share.
NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES
COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE
ADEQUACY OR ACCURACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A
CRIMINAL OFFENSE.
The date of this prospectus is August __, 2006
TABLE OF CONTENTS
Page
----
DUSA..................................................................... i
Risk Factors............................................................. 1
Special Note Regarding Forward Looking Statements........................ 13
Use of Proceeds.......................................................... 14
Selling Shareholders..................................................... 14
Plan of Distribution..................................................... 22
Legal Matters............................................................ 23
Experts.................................................................. 23
Where You Can Find More Information...................................... 23
Incorporation of Certain Documents by Reference.......................... 24
DUSA PHARMACEUTICALS, INC.
ABOUT DUSA
DUSA Pharmaceuticals, Inc. is an integrated specialty dermatology company
focused primarily on the development and sale of our Levulan(R) photodynamic
therapy, or PDT, technology platform, and complementary dermatology products.
Our current products include, among others, Levulan(R) Kerastick(R) 20% Topical
Solution with PDT, the BLU-U(R), Nicomide(R), Nicomide-T(R) and the AVAR(R) line
of products. We acquired all of our products other than Levulan(R) and the
BLU-U(R) in connection with our recent merger with Sirius Laboratories, Inc., or
Sirius, which closed on March 10, 2006.
Our drug, Levulan(R) brand of aminolevulinic acid HCl, or ALA, is used with
light, for use in a broad range of medical conditions. When we use Levulan(R)
and follow it with exposure to light to treat a medical condition, it is known
as Levulan(R) photodynamic therapy, or Levulan(R) PDT. When we use Levulan(R)
and follow it with exposure to light to detect medical conditions it is known as
Levulan(R) photodetection, or Levulan(R) PD. The Levulan(R) Kerastick(R) is our
proprietary applicator that contains our drug.
Two of our products, Levulan(R) Kerastick(R) 20% Topical Solution with PDT
and the BLU-U(R) brand light source were launched in the United States, or U.S.,
in September 2000 for the treatment of actinic keratoses, or AKs, of the face or
scalp. AKs are precancerous skin lesions caused by chronic sun exposure that can
develop over time into a form of skin cancer called squamous cell carcinoma. In
addition, in September 2003 we received clearance from the U.S. Food and Drug
Administration, or FDA, to market the BLU-U(R) without Levulan(R) PDT for the
treatment of moderate inflammatory acne vulgaris and general dermatological
conditions.
Nicomide(R) is an oral prescription vitamin supplement, and Nicomide-T(R)
is a topical cosmetic product. Both of these products target the acne and acne
rosacea markets. We also market the AVAR(R) line of products, which are sodium
sulfacetamide-based products for the treatment of acne.
Historically, we devoted most of our resources to fund research and
development efforts in order to advance the Levulan(R) PDT/PD technology
platform. In addition, we are continuing to evaluate and develop several
potential products that we acquired in our merger with Sirius which target
patients with acne.
As of June 30, 2006, we had an accumulated deficit of approximately
$98,832,000. We expect to continue to incur operating losses until sales of our
products increase substantially. Achieving our goal of becoming a profitable
operating company is dependent upon greater acceptance of our PDT therapy by the
medical and consumer constituencies, increased sales of our products and other
factors contained in this prospectus and in the filings we make with the
Securities and Exchange Commission, or SEC.
As of June 30, 2006, we had a staff of 85 full-time employees and 2
part-time employees, as compared to 64 full-time employees and two part-time
employees at the end of 2005. Following the closing of the Sirius merger, we
expanded our sales capacity which as of June 30, 2006 included 40 persons as
compared to 26 persons at the end of 2005.
Our principal executive offices are located at 25 Upton Drive, Wilmington,
Massachusetts, 01887 and our telephone number is (978) 657-7500. Unless the
context otherwise requires, the terms "we," "our," "us," "the company" and
"DUSA" refer to DUSA Pharmaceuticals, Inc., a New Jersey corporation, and not to
the Selling Shareholders.
ABOUT THE OFFERING AND THIS PROSPECTUS
On March 10, 2006, we acquired all of the outstanding common stock of
Sirius Laboratories, Inc., or Sirius, in exchange for 2,396,245 shares of DUSA
common stock and $8,000,000 in cash. According to the terms of the merger
agreement, the actual number of shares that were issued in the transaction was
derived by dividing
i
$17,000,000 by the average closing price of our shares on The NASDAQ National
Market during the twenty (20) trading day period prior to March 10, 2006. Of the
2,396,245 shares issued in the acquisition, 422,892 shares have been placed in
an escrow account established to secure the indemnification obligations of the
shareholders of Sirius as set forth in the merger agreement. The escrow account
is established for a period of two years and will be used to satisfy liability
claims, if any, made by DUSA. Additionally, an amount of up to $5,000,000 in
cash or our common stock may be paid to the Selling Shareholders based on a
combination of new product approvals or launches and the achievement of certain
pre-determined total cumulative sales milestones for Sirius products prior to
the date that is forty-two months from the date of the closing of the merger.
The issuance of the shares of common stock to the Selling Shareholders in
connection with the merger was exempt from the registration requirements of the
Securities Act, pursuant to Section 4(2) thereof and Regulation D promulgated
thereunder, based in part upon representations that we obtained from each
Selling Shareholder that such person is an "accredited investor" or had a
"purchaser representative" as such terms are defined in Rule 501 of Regulation
D. Furthermore, in connection with the merger, certain of the shares of our
common stock were issued to a Selling Shareholder that is a corporation
organized under the laws of the United Kingdom, in reliance upon the provisions
of Regulation S promulgated under the Securities Act.
We are filing this prospectus as required by the merger agreement,
including the registration rights agreement by and between DUSA and the Selling
Shareholders which was entered into in connection with the merger. We will not
receive any proceeds from the resale of the common stock by the Selling
Shareholders. See the section of this prospectus entitled "Use of Proceeds."
This prospectus relates to the resale of up to 2,396,245 shares of common stock
by the Selling Shareholders identified in this prospectus under the section of
this prospectus entitled "Selling Shareholders." We have agreed to bear all
expenses of registration of the common stock offered by this prospectus.
This prospectus is part of a registration statement that we have filed with
the SEC. The Selling Shareholders may, from time to time, sell the common stock
described in this prospectus. We may prepare a prospectus supplement at any time
to add, update or change the information contained in this prospectus. This
prospectus does not contain all the information you can find in the registration
statement or the exhibits filed with or incorporated by reference into the
registration statement. Whenever a reference is made in this prospectus to an
agreement or other document of ours, be aware that such reference is not
necessarily complete and you should refer to the exhibits that are filed with or
incorporated by reference in the registration statement for a copy of the
agreement or other document. You should read this prospectus and any prospectus
supplement together with the registration statement, the exhibits filed with or
incorporated by reference into the registration statement and the additional
information described under the section of this prospectus entitled "Where You
Can Find More Information."
ii
RISK FACTORS
Investing in our common stock is very speculative and involves a high
degree of risk. You should carefully consider and evaluate all of the
information in, or incorporated by reference in, this prospectus. The following
are among the risks we face related to our business, assets and operations. They
are not the only ones we face. Any of these risks could materially and adversely
affect our business, results of operations and financial condition, which in
turn could materially and adversely affect the trading price of our common stock
and you might lose all or part of your investment.
This prospectus contains forward-looking statements that involve risks and
uncertainties, such as statements of our plans, objectives, expectations and
intentions. We use words such as "anticipate", "believe", "expect"," future" and
"intend" and similar expressions to identify forward-looking statements. Our
actual results could differ materially from those anticipated in these
forward-looking statements for many reasons, including the factors described
below and elsewhere in this prospectus. You should not place undue reliance on
these forward-looking statements, which apply only as of the date of this
prospectus.
RISKS RELATED TO DUSA
WE ARE NOT CURRENTLY PROFITABLE AND MAY NOT BE PROFITABLE IN THE FUTURE UNLESS
WE CAN SUCCESSFULLY MARKET AND SELL SIGNIFICANTLY HIGHER QUANTITIES OF OUR
PRODUCTS.
WE HAVE ONLY LIMITED EXPERIENCE MARKETING AND SELLING PHARMACEUTICAL PRODUCTS
AND, AS A RESULT, OUR REVENUES FROM PRODUCT SALES MAY SUFFER.
If we are unable to successfully market and sell sufficient quantities of
our products, revenues from product sales will be lower than anticipated and our
financial condition may be adversely affected. We are responsible for marketing
our dermatology products in the United States and the rest of the world, except
Canada, and Mexico and Central and South America, where we have distributors. We
are doing so without the experience of having marketed pharmaceutical products
prior to 2000. In October 2003, DUSA began hiring a small direct sales force and
we increased the size of our sales force to market our products in the United
States. In addition, our sales personnel have only recently begun to sell and
market the Sirius products. If our sales and marketing efforts fail, then sales
of the Kerastick(R), the BLU-U(R) and the Sirius Products -- Nicomide(R),
Nicomide-T(R), the AVAR(R) line of products, METED(R), Psoriacap(R) and
Psoriatec(R) will be adversely affected.
IF WE CANNOT IMPROVE PHYSICIAN REIMBURSEMENT AND/OR CONVINCE MORE PRIVATE
INSURANCE CARRIERS TO ADEQUATELY REIMBURSE PHYSICIANS FOR OUR PRODUCT SALES MAY
SUFFER.
Without adequate levels of reimbursement by government health care programs
and private health insurers, the market for our Levulan(R) Kerastick(R) for AK
therapy will be limited. While we continue to support efforts to improve
reimbursement levels to physicians and are working with the major private
insurance carriers to improve coverage for our therapy, if our efforts are not
successful, adoption of our therapy and sales of our products could be
negatively impacted. Although 2005 reimbursement changes related to AK were
made, some physicians still believe that reimbursement levels do not fully
reflect the required efforts to routinely execute our therapy in their
practices.
If insurance companies do not cover, or stop covering products which are
currently covered, our sales could be dramatically reduced.
SINCE WE NOW OPERATE THE ONLY FDA APPROVED MANUFACTURING FACILITY FOR THE
KERASTICK(R) AND CONTINUE TO RELY HEAVILY ON SOLE SUPPLIERS FOR THE MANUFACTURE
OF LEVULAN(R), THE BLU-U(R) AND THE SIRIUS PRODUCTS -- NICOMIDE(R),
NICOMIDE-T(R), THE AVAR(R) LINE OF PRODUCTS, METED(R), PSORIACAP(R) AND
PSORIATEC(R), ANY SUPPLY OR MANUFACTURING PROBLEMS COULD NEGATIVELY IMPACT OUR
SALES.
If we experience problems producing Kerastick(R) units in our facility, or
if any of our contract suppliers fail to supply our requirements for products,
our business, financial condition and results of operations would suffer.
Although we have received approval by the FDA to manufacture the BLU-U(R) and
the Kerastick (R) in our Wilmington, Massachusetts facility, at this time, with
respect to the BLU-U(R) we expect to utilize our own facility only as a back-up
to our current third party manufacturer or
1
for repairs.
We are working with the supplier of the AVAR(R) line of products to address
certain manufacturing concerns. We now expect that inventory of some of these
products will be temporarily depleted for a few months while such concerns are
being addressed and could negatively affect revenues from these products which
accounted for approximately 3% of revenues for the quarter ended June 30, 2006.
Manufacturers and their subcontractors often encounter difficulties when
commercial quantities of products are manufactured for the first time, or large
quantities of new products are manufactured, including problems involving:
- product yields,
- quality control,
- component and service availability,
- compliance with FDA regulations, and
- the need for further FDA approval if manufacturers make material
changes to manufacturing processes and/or facilities.
We cannot guarantee that problems will not arise with production yields,
costs or quality as we and our suppliers seek to increase production. Any
manufacturing problems could delay or limit our supplies which would hinder our
marketing and sales efforts.
If our facility, any facility of our contract manufacturers, or any
equipment in those facilities is damaged or destroyed, we may not be able to
quickly or inexpensively replace it. Likewise, if there are any quality or
supply problems with any components or materials needed to manufacturer our
products, we may not be able to quickly remedy the problem(s). Any of these
problems could cause our sales to suffer.
ANY FAILURE TO COMPLY WITH ONGOING GOVERNMENTAL REGULATIONS IN THE UNITED STATES
AND ELSEWHERE WILL LIMIT OUR ABILITY TO MARKET OUR PRODUCTS.
The manufacture and marketing of our products, the Levulan(R) Kerastick(R)
with the BLU-U(R) for AKs, the BLU-U(R) without Levulan(R) to treat moderate
inflammatory acne and the Sirius products -- Nicomide(R), Nicomide-T(R), the
AVAR(R) line of products, METED(R), Psoriacap(R) and Psoriatec(R), are subject
to continuing FDA review as well as comprehensive regulation by the FDA and by
state and local regulatory authorities. These laws require, among other things:
- approval of manufacturing facilities, including adherence to good
manufacturing and laboratory practices during production and storage,
- controlled research and testing of some of these products even after
approval, and
- control of marketing activities, including advertising and labeling.
If we, or any of our contract manufacturers, fail to comply with these
requirements, we may be limited in the jurisdictions in which we are permitted
to sell our products. Additionally, if we or our manufacturers fail to comply
with applicable regulatory approval requirements, a regulatory agency may also:
- send us warning letters,
- impose fines and other civil penalties on us,
- seize our products,
2
- suspend our regulatory approvals,
- refuse to approve pending applications or supplements to approved
applications filed by us,
- refuse to permit exports of our products from the United States,
- require us to recall products,
- require us to notify physicians of labeling changes and/or product
related problems,
- impose restrictions on our operations, and/or
- criminally prosecute us.
We and our manufacturers must continue to comply with the FDA's Good
Manufacturing Practice, commonly known as cGMP, and Quality System Regulation,
or QSR, and equivalent foreign regulatory requirements. The cGMP requirements
govern quality control and documentation policies and procedures. In complying
with cGMP and foreign regulatory requirements, we and our third-party
manufacturers will be obligated to expend time, money and effort in production,
record keeping and quality control to assure that our products meet applicable
specifications and other requirements.
As part of our FDA approval for the Levulan(R) Kerastick(R) for AK, we were
required to conduct two Phase IV follow-up studies. We successfully completed
the first study; and submitted our final report on the second study to the FDA
in January 2004. The FDA could request additional information and/or studies.
Additionally, if previously unknown problems with the product, a manufacturer or
its facility are discovered in the future, changes in product labeling
restrictions or withdrawal of the product from the market may occur.
Manufacturing facilities are subject to ongoing periodic inspection by the
FDA, including unannounced inspections. We cannot guarantee that our third-party
supply sources, or our own Kerastick(R) facility, will continue to meet all
applicable FDA regulations. If we, or any of our manufacturers, including
without limitation, the manufacture of the AVAR(R) products, fail to maintain
compliance with FDA regulatory requirements, it would be time consuming and
costly to remedy the problem(s) or to qualify other sources. These consequences
could have an adverse effect on our financial condition and operations.
Certain of the Sirius products acquired in connection with the merger must
meet certain minimum manufacturing and labeling standards established by the FDA
and applicable to products marketed without approved marketing applications. FDA
regulates such products under its marketed unapproved drugs compliance policy
guide entitled, "Marketed New Drugs without Approved NDAs or ANDAs." Under this
policy, FDA recognizes that certain unapproved products, based on the
introduction date of their active ingredients and the lack of safety concerns,
have been marketed for many years and, at this time, will not be the subject of
any enforcement action. We believe that so long as we comply with applicable
manufacturing and labeling standards we will be consistent with FDA's current
enforcement policy. There can be no assurance that the FDA will continue this
policy or not take a contrary position with any individual products. If the FDA
were to do so, we may be required to seek FDA approval for these products,
market these products as over-the-counter products or as dietary supplements
under applicable legislation, or withdraw such products from the market.
IF PRODUCT SALES DO NOT INCREASE SIGNIFICANTLY WE MAY NOT BE ABLE TO ADVANCE
DEVELOPMENT OF OUR OTHER POTENTIAL PRODUCTS AS QUICKLY AS WE WOULD LIKE TO,
WHICH WOULD DELAY THE APPROVAL PROCESS AND MARKETING OF NEW POTENTIAL PRODUCTS.
If we do not generate sufficient revenues from our approved products, we
may be forced to delay or abandon some or all of our product development
programs. The pharmaceutical development and commercialization process is time
consuming and costly, and any delays might result in higher costs which could
adversely affect our financial condition. Without sufficient product sales, we
might be required to seek additional funding. There is no guarantee that
adequate funding sources could be found to continue the development of all our
potential products.
3
We might be required to commit substantially greater capital than we have
available to research and development of such products and we may not have
sufficient funds to complete all or any of our development programs.
THE COMMERCIAL SUCCESS OF ANY PRODUCTS THAT WE MAY DEVELOP WILL DEPEND UPON THE
DEGREE OF MARKET ACCEPTANCE OF OUR PRODUCTS AMONG PHYSICIANS, PATIENTS, HEALTH
CARE PAYORS, PRIVATE HEALTH INSURERS AND THE MEDICAL COMMUNITY.
Our ability to commercialize any products that we may develop will be
highly dependent upon the extent to which these products gain market acceptance
among physicians, patients, health care payors, such as Medicare and Medicaid,
private health insurers, including managed care organizations and group
purchasing organizations, and the medical community. If these products do not
achieve an adequate level of acceptance, we may not generate material product
revenues, and we may not become profitable. The degree of market acceptance of
our product candidates, if approved for commercial sale, will depend on a number
of factors, including:
- the effectiveness, or perceived effectiveness, of our products in
comparison to competing products;
- the existence of any significant side effects, as well as their
severity in comparison to any competing products;
- potential advantages over alternative treatments;
- the ability to offer our products for sale at competitive prices;
- relative convenience and ease of administration;
- the strength of marketing and distribution support; and
- sufficient third-party coverage or reimbursement.
WE HAVE SIGNIFICANT LOSSES AND ANTICIPATE CONTINUED LOSSES.
We have a history of operating losses. We expect to have continued losses
until sales of our products increase substantially. We incurred net losses of
$4,653,954 for the quarter ended June 30, 2006. We incurred net losses of
$14,998,709 for the year ended December 31, 2005 and $15,628,980 for the year
ended December 31, 2004. As of June 30, 2006, our accumulated deficit was
approximately $98,832,000. We cannot predict whether any of our products will
achieve significant enough market acceptance or generate sufficient revenues to
enable us to become profitable.
IF WE ARE UNABLE TO PROTECT OUR PROPRIETARY TECHNOLOGY, TRADE SECRETS OR
KNOW-HOW, WE MAY NOT BE ABLE TO OPERATE OUR BUSINESS PROFITABLY.
WE HAVE LIMITED PATENT PROTECTION AND IF WE ARE UNABLE TO PROTECT OUR
PROPRIETARY RIGHTS, COMPETITORS MIGHT BE ABLE TO DEVELOP SIMILAR PRODUCTS TO
COMPETE WITH OUR PRODUCTS AND TECHNOLOGY.
Our ability to compete successfully depends, in part, on our ability to
defend patents that have issued, obtain new patents, protect trade secrets and
operate without infringing the proprietary rights of others. We have no compound
patent protection for our Levulan(R) brand of the compound ALA. Our basic ALA
patents are for methods of detecting and treating various diseased tissues using
ALA (or related compounds called precursors), in combination with light. We own
or exclusively license ALA patents and patent applications related to the
following:
- methods of using ALA and its unique physical forms in combination with
light,
- compositions and apparatus for those methods, and
4
- unique physical forms of ALA.
We have limited ALA patent protection outside the United States, which may
make it easier for third-parties to compete there. Our basic method of treatment
patents and applications have counterparts in only six foreign countries, and
certain countries under the European Patent Convention. Even where we have
patent protection, there is no guarantee that we will be able to enforce our
patents. Additionally, enforcement of a given patent may not be practicable or
an economically viable alternative.
Some of the indications for which we are developing therapies may not be
covered by the claims in any of our existing patents. Even with the issuance of
additional patents to DUSA, other parties are free to develop other uses of ALA,
including medical uses, and to market ALA for such uses, assuming that they have
obtained appropriate regulatory marketing approvals. ALA in the chemical form
has been commercially supplied for decades, and is not itself subject to patent
protection. There are reports of third-parties conducting clinical studies with
ALA in countries outside the United States where PARTEQ, the licensor of our ALA
patents, does not have patent protection. In addition, a number of third-parties
are seeking patents for uses of ALA not covered by our patents. These other
uses, whether patented or not, and the commercial availability of ALA, could
limit the scope of our future operations because ALA products could come on the
market which would not infringe our patents but would compete with our
Levulan(R) products even though they are marketed for different uses.
While we attempt to protect our proprietary information as trade secrets
through agreements with each employee, licensing partner, consultant,
university, pharmaceutical company and agent, we cannot guarantee that these
agreements will provide effective protection for our proprietary information. It
is possible that:
- these persons or entities might breach the agreements,
- we might not have adequate remedies for a breach, and/or
- our competitors will independently develop or otherwise discover our
trade secrets.
Nicomide is covered by a U.S. patent which issued in December 2005. River's
Edge Pharmaceuticals LLC has filed an application with the U.S. Patent and
Trademark Office for the reexamination of the patent. If the USPTO finds that
the patent is invalid, River's Edge and other generics will be able to compete
with Nicomide. Recently two new products have been launched that could compete
with Nicomide(R).
PATENT LITIGATION IS EXPENSIVE, AND WE MAY NOT BE ABLE TO AFFORD THE COSTS.
The costs of litigation or any proceeding relating to our intellectual
property rights could be substantial even if resolved in our favor. Some of our
competitors have far greater resources than we do and may be better able to
afford the costs of complex patent litigation. For example, third-parties may
infringe one or more of our patents, and we are spending significant resources
to enforce our patent rights. Also, in a lawsuit against a third-party for
infringement of our patents in the United States, that third-party has
challenged the validity of our patent(s). We cannot guarantee that a third-party
will not claim, with or without merit, that we have infringed their patent(s) or
misappropriated their proprietary material. Defending this type of legal action
involves considerable expense and could negatively affect our financial results.
Additionally, if a third-party were to file a United States patent
application in the United States, or be issued a patent claiming technology also
claimed by us in a pending United States application(s), we may be required to
participate in interference proceedings in the United States Patent and
Trademark Office to determine the priority of the invention. A third-party could
also request the declaration of a patent interference between one of our issued
United States patents and one of its patent applications. Any interference
proceedings likely would require participation by us and/or PARTEQ, could
involve substantial legal fees and result in a loss or lessening of our patent
protection.
5
On March 28, 2006, a lawsuit was filed by River's Edge Pharmaceuticals, LLC
against us alleging, among other things, that, prior to the merger, Sirius
Laboratories, Inc. agreed to authorize River's Edge to market a generic version
of Nicomide(R), and that the United States patent covering Nicomide(R) issued to
Sirius in December, 2005 is invalid. The declaratory judgment suit was filed in
the United States District Court for the Northern District of Georgia,
Gainesville Division and has been dismissed. Nicomide is one of the key
products DUSA acquired from Sirius in its merger. On April 20, 2006, we filed a
patent infringement suit in the United States District Court in Trenton, New
Jersey alleging that a River's Edge niacinamide product infringes U.S. Patent
No. 6,979,468, the patent that covers Nicomide(R). On May 12, 2006, the United
States District Court issued a preliminary injunction against River's Edge
enjoining River's Edge from selling its niacinamide formula drug as a generic
substitute for Nicomide(R). However, if we do not ultimately prevail in our
lawsuit, or the Nicomide(R) patent is found to be invalid, our revenues from
sales of Nicomide(R) could decrease significantly.
During 2005 and 2006, we filed several lawsuits against a chemical
supplier, compounding pharmacies and physicians alleging violations of patent
law. While we have been successful in obtaining a default judgment against one
compounding pharmacy, settled another suit, and have obtained consent judgments
from several physicians, we do not know whether these lawsuits will prevent
others from infringing our patents or whether we will be successful in stopping
these activities which we believe are negatively affecting our revenues.
WE HAVE ONLY 2 THERAPIES THAT HAVE RECEIVED REGULATORY APPROVAL OR
CLEARANCE AND WE CANNOT PREDICT WHETHER WE WILL EVER DEVELOP OR COMMERCIALIZE
ANY OTHER PRODUCTS.
EXCEPT FOR THE LEVULAN(R) KERASTICK(R) WITH THE BLU-U(R) TO TREAT AKS, THE USE
OF THE BLU-U(R) ALONE TO TREAT MODERATE INFLAMMATORY ACNE, AND THE SIRIUS
PRODUCTS -- NICOMIDE(R), NICOMIDE-T(R), THE AVAR(R) LINE OF PRODUCTS, METED(R),
PSORIACAP(R) AND PSORIATEC(R), ALL OF OUR POTENTIAL PRODUCTS ARE IN EARLY STAGES
OF DEVELOPMENT AND MAY NEVER RESULT IN ANY COMMERCIALLY SUCCESSFUL PRODUCTS.
We do not know if the Levulan(R) Kerastick(R), the BLU-U(R) products will
ever be commercially successful. To be profitable, we must successfully
research, develop, obtain regulatory approval for, manufacture, introduce,
market and distribute our products. Except for Levulan(R) PDT for AKs, the
BLU-U(R) for acne and the currently marketed Sirius products, all of our other
potential Levulan(R) and other potential product candidates which we acquired in
our merger with Sirius, are at an early stage of development and subject to the
risks of failure inherent in the development of new pharmaceutical products and
products based on new technologies. These risks include:
- delays in product development, clinical testing or manufacturing,
- unplanned expenditures in product development, clinical testing or
manufacturing,
- failure in clinical trials or failure to receive regulatory approvals,
- emergence of superior or equivalent products,
- inability to market products due to third-party proprietary rights,
and
- failure to achieve market acceptance.
We cannot predict how long the development of our investigational stage
products will take or whether they will be medically effective. We cannot be
sure that a successful market will continue to develop for our Levulan(R) drug
technology.
6
WE MUST RECEIVE SEPARATE APPROVAL FOR EACH OF OUR POTENTIAL PRODUCTS BEFORE WE
CAN SELL THEM COMMERCIALLY IN THE UNITED STATES OR ABROAD.
All of our potential Levulan(R) products will require the approval of the
FDA before they can be marketed in the United States. If we fail to obtain the
required approvals for these products our revenues will be limited. Before an
application to the FDA seeking approval to market a new drug, called an NDA, can
be filed, a product must undergo, among other things, extensive animal testing
and human clinical trials. The process of obtaining FDA approvals can be
lengthy, costly, and time-consuming. Following the acceptance of an NDA, the
time required for regulatory approval can vary and is usually 1 to 3 years or
more. The FDA may require additional animal studies and/or human clinical trials
before granting approval. Our Levulan(R) PDT products are based on relatively
new technology. To the best of our knowledge, the FDA has approved only 3 drugs
for use in photodynamic therapy, including Levulan(R). This factor may lengthen
the approval process. We face much trial and error and we may fail at numerous
stages along the way.
We cannot predict whether we will obtain approval for any of our potential
products. Data obtained from preclinical testing and clinical trials can be
susceptible to varying interpretations which could delay, limit or prevent
regulatory approvals. Future clinical trials may not show that Levulan(R) PDT or
photodetection, known as PD, is safe and effective for any new use we are
studying. In addition, delays or disapprovals may be encountered based upon
additional governmental regulation resulting from future legislation or
administrative action or changes in FDA policy. During September 2005, the FDA
issued guidance for the pharmaceutical industry regarding the development of new
drugs for acne vulgaris treatment. We are developing Levulan(R) PDT for acne. As
a result, it is likely that the costs and time to approval associated with
seeking regulatory approval of this indication will be increased. The FDA may
issue additional guidance in the future, which may result on additional costs
and delays. We must also obtain foreign regulatory clearances before we can
market any potential products in foreign markets. The foreign regulatory
approval process includes all of the risks associated with obtaining FDA
marketing approval and may impose substantial additional costs.
Certain of the Sirius products acquired in connection with our merger must
meet certain minimum manufacturing and labeling standards established by the FDA
and applicable to products marketed without approved marketing applications. FDA
regulates such products under its marketed unapproved drugs compliance policy
guide entitled, "Marketed New Drugs without Approved NDAs or ANDAs." Under this
policy, FDA recognizes that certain unapproved products, based on the
introduction date of their active ingredients and the lack of safety concerns,
have been marketed for many years and, at this time, will not be the subject of
any enforcement action. We believe that so long as we comply with applicable
manufacturing and labeling standards we will be consistent with FDA's current
enforcement policy. There can be no assurance that the FDA will continue this
policy or not take a contrary position with any individual products. If the FDA
were to do so, we may be required to seek FDA approval for these products,
market these products as over-the-counter products or as dietary supplements
under applicable legislation, or withdraw such products from the market.
IF WE ARE UNABLE TO OBTAIN THE NECESSARY CAPITAL TO FUND OUR OPERATIONS, WE WILL
HAVE TO DELAY OUR DEVELOPMENT PROGRAMS AND MAY NOT BE ABLE TO COMPLETE OUR
CLINICAL TRIALS.
Since our current sales goals for our products may not be met in the
future, we may need substantial additional funds to fully develop, manufacture,
market and sell our other potential products. We may obtain funds through other
public or private financings, including equity financing, and/or through
collaborative arrangements. We cannot predict whether any financing will be
available at all or on acceptable terms.
Dependent on the extent of available funding, we may delay, reduce in scope
or eliminate some of our research and development programs. We may also choose
to license rights to third parties to commercialize products or technologies
that we would otherwise have attempted to develop and commercialize on our own
which could reduce our potential revenues.
WE ARE EXPOSED TO RISKS ASSOCIATED WITH ACQUISITIONS.
On March 10, 2006, we acquired Sirius Laboratories, Inc. We may in the
future make other acquisitions of, or significant investments in, businesses
with complementary products, services and/or technologies. Acquisitions
7
involve numerous risks, including, but not limited to:
- difficulties and increased costs in connection with integration of the
personnel, operations, technologies and products of acquired
companies;
- diversion of management's attention from other operational matters;
- the potential loss of key employees;
- the potential loss of key collaborators;
- lack of synergy, or the inability to realize expected synergies,
resulting from the acquisition;
- acquired intangible assets becoming impaired as a result of
technological advancements or worse-than-expected performance of the
acquired company;
- the potential for unexpected liabilities; and
- use of cash which could be difficult to replace on reasonable terms.
Mergers and acquisitions are inherently risky, and the inability to
effectively manage these risks could materially and adversely affect our
business, financial condition and results of operations. In addition, there may
be liabilities that we fail, or are unable, to discover in the course of
performing due diligence investigations on any company that we may acquire, or
have recently acquired. Also, there may be additional costs relating to
acquisitions including, but not limited to, possible purchase price adjustments.
Any of our rights to indemnification from sellers to us, even if obtained, may
not be enforceable, collectible or sufficient in amount, scope or duration to
fully offset the possible liabilities associated with the business or property
acquired. Any such liabilities, individually or in the aggregate, could have a
material adverse effect on our business.
The merger between DUSA and Sirius may be more difficult, costly or time
consuming than expected, and we may not be able to successfully integrate our
business with Sirius' business.
Upon completion of our merger with Sirius, we began to integrate our
operations with those of Sirius. Although we have not experienced significant
difficulties to date, as the integration process continues, it is possible that
we may face difficulties which may result in, among other things, disruptions in
our ongoing operations. For example, we may experience differences in the two
companies' business procedures, controls or personnel policies, and there could
be problems that affect our ongoing relationships with our customers or that
affect our ability to realize all anticipated benefits of the merger. Some of
these difficulties include, without limitation, the loss of key employees and
customers, the disruption of ongoing business relationships, and possible
inconsistencies in standards, controls, procedures and policies. The success of
our merger with Sirius depends on our ability to successfully merge corporate
cultures and operational and financial systems, integrate and retain the
customer base of the acquired business, realize cost reduction synergies; and as
necessary, retain key management members and technical personnel of acquired
companies. If we fail to integrate Sirius' business and operations successfully,
that failure could have a material adverse effect on our business.
BECAUSE OF THE NATURE OF OUR BUSINESS, THE LOSS OF KEY MEMBERS OF OUR MANAGEMENT
TEAM COULD DELAY ACHIEVEMENT OF OUR GOALS.
We are a small company with only 87 employees, including 2 part-time
employees as of June 30, 2006. We are highly dependent on several key
officer/employees with specialized scientific and technical skills without whom
our business, financial condition and results of operations would suffer,
especially in the photodynamic therapy portion of our business. The
photodynamic therapy industry is still quite small and the number of experts is
limited. The loss of these key employees could cause significant delays in
achievement of our business and research goals since very few people with their
expertise could be hired. Our growth and future success will depend, in large
part, on the continued contributions of these key individuals as well as our
ability to motivate and retain other qualified personnel in our specialty drug
and light device areas
8
OUR COLLABORATIONS WITH OUTSIDE SCIENTISTS MAY BE SUBJECT TO RESTRICTION AND
CHANGE.
We work with scientific and clinical advisors and collaborators at academic
and other institutions that assist us in our research and development efforts.
These scientists and advisors are not our employees and may have other
commitments that limit their availability to us. Although our advisors and
collaborators generally agree not to do competing work, if a conflict of
interest between their work for us and their work for another entity arises, we
may lose their services. In addition, although our advisors and collaborators
sign agreements not to disclose our confidential information, it is possible
that valuable proprietary knowledge may become publicly known through them.
RISKS RELATED TO OUR INDUSTRY
PRODUCT LIABILITY AND OTHER CLAIMS AGAINST US MAY REDUCE DEMAND FOR OUR PRODUCTS
OR RESULT IN DAMAGES.
WE ARE SUBJECT TO RISK FROM POTENTIAL PRODUCT LIABILITY LAWSUITS WHICH
COULD NEGATIVELY AFFECT OUR BUSINESS.
The development, manufacture and sale of medical products exposes us to
product liability claims related to the use or misuse of our products. Product
liability claims can be expensive to defend and may result in significant
judgments against us. A successful claim in excess of our insurance coverage
could materially harm our business, financial condition and results of
operations. Additionally, we cannot guarantee that continued product liability
insurance coverage will be available in the future at acceptable costs. If the
cost is too high, we may have to self-insure.
OUR BUSINESS INVOLVES ENVIRONMENTAL RISKS AND WE MAY INCUR SIGNIFICANT COSTS
COMPLYING WITH ENVIRONMENTAL LAWS AND REGULATIONS.
We have used various hazardous materials, such as mercury in fluorescent
tubes in our research and development activities. We are subject to federal,
state and local laws and regulations which govern the use, manufacture, storage,
handling and disposal of hazardous materials and specific waste products. Now
that we have established our own production line for the manufacture of the
Kerastick(R), we are subject to additional environmental laws and regulations.
We believe that we are in compliance in all material respects with currently
applicable environmental laws and regulations. However, we cannot guarantee that
we will not incur significant costs to comply with environmental laws and
regulations in the future. We also cannot guarantee that current or future
environmental laws or regulations will not materially adversely affect our
operations, business or assets. In addition, although we believe our safety
procedures for handling and disposing of these materials comply with federal,
state and local laws and regulations, we cannot completely eliminate the risk of
accidental contamination or injury from these materials. In the event of such an
accident, we could be held liable for any resulting damages, and this liability
could exceed our resources.
WE MAY NOT BE ABLE TO COMPETE AGAINST TRADITIONAL TREATMENT METHODS OR KEEP UP
WITH RAPID CHANGES IN THE BIOTECHNOLOGY AND PHARMACEUTICAL INDUSTRIES THAT COULD
MAKE SOME OR ALL OF OUR PRODUCTS NON-COMPETITIVE OR OBSOLETE.
COMPETING PRODUCTS AND TECHNOLOGIES BASED ON TRADITIONAL TREATMENT METHODS MAY
MAKE SOME OR ALL OF OUR PROGRAMS OR POTENTIAL PRODUCTS NONCOMPETITIVE OR
OBSOLETE.
Well-known pharmaceutical, biotechnology and medical device companies are
marketing well-established therapies for the treatment of many of the same
conditions that we are seeking to treat, including AKs, acne, rosacea,
photodamaged skin and Barrett's esophagus. Doctors may prefer to use familiar
methods, rather than trying our products. Reimbursement issues affect the
economic competitiveness of our products as compared to other more traditional
therapies.
Many companies are also seeking to develop new products and technologies,
and receiving approval for
9
medical conditions for which we are developing treatments. Our industry is
subject to rapid, unpredictable and significant technological change.
Competition is intense. Our competitors may succeed in developing products that
are safer or more effective than ours. Many of our competitors have
substantially greater financial, technical and marketing resources than we have.
In addition, several of these companies have significantly greater experience
than we do in developing products, conducting preclinical and clinical testing
and obtaining regulatory approvals to market products for health care.
We cannot guarantee that new drugs or future developments in drug
technologies will not have a material adverse effect on our business. Increased
competition could result in:
- price reductions,
- lower levels of third-party reimbursements,
- failure to achieve market acceptance, and
- loss of market share, any of which could adversely affect our
business. Further, we cannot give any assurance that developments by
our competitors or future competitors will not render our technology
obsolete.
On May 30, 2006, we entered into a patent license agreement with PhotoCure
ASA whereby DUSA granted a non-exclusive license to PhotoCure under the patents
DUSA licenses from PARTEQ, the licensing arm of Queens University, Kingston,
Ontario Canada for esters of aminolevulinic acid ("ALA"). ALA is the active
ingredient in DUSA's Levulan(R) products. Furthermore, DUSA granted a
non-exclusive license to PhotoCure for its existing formulations of its
Hexvix(R) and Metvix(R) (known in the United States as Metvixia(R)) products for
any DUSA patents that may issue or be licensed by DUSA in the future. PhotoCure
received FDA approval to market Metvixia for treatment of AKs in July 2004 and
it would be directly competitive with our Levulan Kerastick product should
PhotoCure decide to begin marketing this product. While we are entitled to
royalties from PhotoCure on its net sales of Metvixia, this product may
adversely affect our ability to maintain or increase our market.
OUR PRODUCTS MAY LOSE MARKET SHARE IF NEW MANUFACTURERS BEGIN PRODUCING
COMPETING PRODUCTS THAT ARE ABLE TO PENETRATE OUR MARKET.
WE HAVE LEARNED THAT COMPOUNDING PHARMACIES ARE PRODUCING A FORM OF
AMINOLEVULINIC ACID HCL AND ARE MARKETING IT TO THE MEDICAL COMMUNITY.
We are aware that there are compounding pharmacies that market compounded
versions of aminolevulinic acid HCl as an alternative to our Levulan(R) product.
On January 31, 2005, we filed a lawsuit in the United States District Court for
the District of Arizona against The Cosmetic Pharmacy of Tucson, Arizona
alleging violations of the Lanham Act for false advertising and trademark
infringement and of United States patent law. A motion for default judgment was
granted on July 25, 2005 in our favor for failure of The Cosmetic Pharmacy of
Tucson to appear, together with injunctive relief and attorney fees and costs in
the amount of approximately $20,700. On December 27, 2004, we filed a lawsuit in
United States District Court for the District of Massachusetts against New
England Compounding Pharmacy, Inc. of Framingham, Massachusetts alleging
violations of United States patent law which has now settled. More recently, we
have sued a chemical supplier, Spectrum Pharmacy Products, in United States
District Court for the District of Arizona, alleging that it induces physicians
to infringe patents licensed to us, among other things. While we believe that
certain actions of compounding pharmacies go beyond the activities which are
permitted under the Food, Drug and Cosmetic Act and have advised the FDA and
local health authorities of our concerns, we cannot be certain that our lawsuits
will be successful in curbing the practices of these companies or that
regulatory authorities will intervene to stop their activities. In addition,
there may be other compounding pharmacies which are following FDA guidelines, or
others conducting illegal activities of which we are not aware, which may be
negatively impacting our sales revenues.
We also learned that River's Edge was marketing an alternative niacinamide
product and we filed a lawsuit against them alleging that the River's Edge
product infringes our patent. On May 12, 2006, the United States District Court
in Trenton, New Jersey, issued a preliminary injunction against River's Edge
enjoining River's Edge from selling its niacinamide formula drug as a generic
substitute for Nicomide(R).
10
If generic manufacturers launch products to compete with Nicomide in spite
of our patent position, or if a court or the United States Patent and Trademark
Office determine that our patent is invalid, these manufacturers may erode our
market and negatively impact our sales revenues, liquidity and operations.
OUR COMPETITORS IN THE BIOTECHNOLOGY AND PHARMACEUTICAL INDUSTRIES MAY HAVE
BETTER PRODUCTS, MANUFACTURING CAPABILITIES OR MARKETING EXPERTISE.
We anticipate that we will face increased competition as the scientific
development of PDT and PD advances and new companies enter our markets. Several
companies are developing PDT agents other than Levulan(R). These include: QLT
Inc. (Canada); Axcan Pharma Inc. (U.S.); Miravant, Inc. (U.S.); and
Pharmacyclics, Inc. (U.S.). We are also aware of several companies
commercializing and/or conducting research with ALA or ALA-related compounds,
including: medac GmbH and photonamic GmbH & Co. KG (Germany); PhotoTherapeutics,
Inc. (U.K.) and PhotoCure ASA (Norway) which entered into a marketing agreement
with Galderma S.A. for countries outside of Nordic countries for certain
dermatology indications. There are many pharmaceutical companies that compete
with us in the field of dermatology, particularly in the acne and rosacea
markets.
PhotoCure has received marketing approval of its ALA precursor (ALA
methyl-ester) compound for PDT treatment of AKs and basal cell carcinoma in the
European Union, New Zealand, Australia and countries in Scandinavia. We believe
that PhotoCure's marketing partner will begin to market its product in direct
competition with Levulan(R) in the U.S. under the terms of our recently entered
patent license agreement and we may lose market share.
Axcan Pharma Inc. has received FDA approval for the use of its product,
PHOTOFRIN(R), for PDT in the treatment of high grade dysplasia associated with
Barrett's esophagus. Axcan is the first company to market a PDT therapy for this
indication, which we are also pursuing.
We expect that our principal methods of competition with other PDT
companies will be based upon such factors as:
- the ease of administration of our method of PDT,
- the degree of generalized skin sensitivity to light,
- the number of required doses,
- the selectivity of our drug for the target lesion or tissue of
interest, and
- the type and cost of our light systems.
Our primary competition in the acne and rosacea markets include oral and
topical antibiotics, other topical prescription and over-the-counter products,
as well as various laser and non-laser light treatments. The market is highly
competitive and other large and small companies have more experience than we do
which could make it difficult for us to penetrate the market. We are also aware
of new products that were launched recently which could compete with
Nicomide(R) and the AVAR(R) line of products which could negatively impact our
market share.
RISKS RELATED TO OUR STOCK
IF OUTSTANDING OPTIONS, WARRANTS AND RIGHTS ARE CONVERTED, THE VALUE OF THOSE
SHARES OF COMMON STOCK OUTSTANDING JUST PRIOR TO THE CONVERSION WILL BE DILUTED.
As of June 30, 2006 there were outstanding options and warrants to purchase
3,181,438 shares of common stock, with exercise prices ranging from U.S. $1.60
to $31.00 per share, and of CDN $6.79 per share, respectively. The holders of
the options and warrants have the opportunity to profit if the market price for
the common stock exceeds the exercise price of their respective securities,
without assuming the risk of ownership. The holders are likely to exercise their
securities when we would probably be able to raise capital from the public on
terms more
11
favorable than those provided in these securities.
RESULTS OF OUR OPERATIONS AND GENERAL MARKET CONDITIONS FOR SPECIALTY
PHARMACEUTICAL AND BIOTECHNOLOGY STOCKS COULD RESULT IN SUDDEN CHANGES IN THE
MARKET VALUE OF OUR STOCK.
The price of our common stock has been highly volatile. These fluctuations
create a greater risk of capital losses for our shareholders as compared to less
volatile stocks. From January 1, 2005 to August 7, 2006, the price of our stock
has ranged from a low of $3.87 to a high of $16.30. Factors that contributed to
the volatility of our stock during this period included:
- quarterly levels of product sales;
- clinical trial results;
- general market conditions;
- patent litigation;
- increased marketing activities; and
- changes in third-party payor reimbursement for our therapy.
The significant general market volatility in similar stage pharmaceutical
and biotechnology companies made the market price of our common stock even more
volatile.
SIGNIFICANT FLUCTUATIONS IN ORDERS FOR OUR PRODUCTS, ON A MONTHLY AND QUARTERLY
BASIS, ARE COMMON BASED ON EXTERNAL FACTORS AND SALES PROMOTION ACTIVITIES.
THESE FLUCTUATIONS COULD INCREASE THE VOLATILITY OF OUR STOCK PRICE.
The price of our common stock may be affected by the amount of quarterly
shipments of our products to end-users. Since our PDT products are still in the
early stages of adoption, and sales volumes are still low, a number of factors
could affect product sales levels and growth rates in any period. These could
include the timing of medical conferences, sales promotion activities, and large
volume purchases by our higher usage customers. In addition, seasonal
fluctuations in the number of patients seeking treatment at various times during
the year could impact sales volumes. These factors could, in turn, affect the
volatility of our stock price.
EFFECTING A CHANGE OF CONTROL OF DUSA WOULD BE DIFFICULT, WHICH MAY DISCOURAGE
OFFERS FOR SHARES OF OUR COMMON STOCK.
Our certificate of incorporation authorizes the board of directors to issue
up to 100,000,000 shares of stock, 40,000,000 of which are common stock. The
board of directors has the authority to determine the price, rights, preferences
and privileges, including voting rights, of the remaining 60,000,000 shares
without any further vote or action by the shareholders. The rights of the
holders of our common stock will be subject to, and may be adversely affected
by, the rights of the holders of any preferred stock that may be issued in the
future.
On September 27, 2002, we adopted a shareholder rights plan at a special
meeting of DUSA's board of directors. The rights plan could discourage, delay or
prevent a person or group from acquiring 15% or more (or 20% or more in the case
of certain parties) of our common stock, thereby limiting, perhaps, the ability
of our shareholders to benefit from such a transaction.
The rights plan provides for the distribution of one right as a dividend
for each outstanding share of our common stock to holders of record as of
October 10, 2002. Each right entitles the registered holder to purchase one
one-thousandths of a share of preferred stock at an exercise price of $37.00 per
right. The rights will be exercisable subsequent to the date that a person or
group either has acquired, obtained the right to acquire, or commences or
12
discloses an intention to commence a tender offer to acquire, 15% or more of our
outstanding common stock (or 20% of the outstanding common stock in the case of
a shareholder or group who beneficially held in excess of 15% at the record
date), or if a person or group is declared an "Adverse Person", as such term is
defined in the rights plan. The rights may be redeemed by DUSA at a redemption
price of one one-hundredth of a cent per right until ten days following the date
the person or group acquires, or discloses an intention to acquire, 15% or 20%
or more, as the case may be, of DUSA, or until such later date as may be
determined by the our board of directors.
Under the rights plan, if a person or group acquires the threshold amount
of common stock, all holders of rights (other than the acquiring person or
group) may, upon payment of the purchase price then in effect, purchase shares
of common stock of DUSA having a value of twice the purchase price. In the event
that we are involved in a merger or other similar transaction where DUSA is not
the surviving corporation, all holders of rights (other than the acquiring
person or group) shall be entitled, upon payment of the purchase price then in
effect, to purchase common stock of the surviving corporation having a value of
twice the purchase price. The rights will expire on October 10, 2012, unless
previously redeemed. Our board of directors has also adopted certain amendments
to DUSA's certificate of incorporation consistent with the terms of the rights
plan.
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This prospectus includes or incorporates forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, as amended. All statements, other than
statements of historical facts, included or incorporated in this prospectus
regarding our strategy, future operations, financial position, future revenues,
projected costs, prospects, plans and objectives of management are
forward-looking statements. The words "anticipates," "believes," "estimates,"
"expects," "intends," "may," "plans," "projects," "will," "would" and similar
expressions are intended to identify forward-looking statements, although not
all forward-looking statements contain these identifying words. We cannot
guarantee that we actually will achieve the plans, intentions or expectations
disclosed in our forward-looking statements and you should not place undue
reliance on our forward-looking statements. Actual results or events could
differ materially from the plans, intentions and expectations disclosed in the
forward-looking statements we make. We have included important factors in the
cautionary statements included or incorporated in this prospectus, particularly
under the heading "Risk Factors", that we believe could cause actual results or
events to differ materially from the forward-looking statements that we make.
Our forward-looking statements do not reflect the potential impact of any future
acquisitions, mergers, dispositions, joint ventures or investments we may make.
We do not assume any obligation to update any forward-looking statements.
You should not unduly rely on forward-looking statements contained or
incorporated by reference in this prospectus. Actual results or outcomes may
differ materially from those predicted in our forward-looking statements due to
the risks and uncertainties inherent in our business, including among other
items, risks and uncertainties including, without limitation statements
regarding our use of estimates and assumptions in the preparation of our
financial statements and policies, including certain pro forma financial
statements and the impact on us of the adoption of certain accounting standards,
our obligation to make certain milestone payments to third parties, our beliefs
and intent regarding the manufacture of our products and the availability of
inventory of our products, the outcome and costs of litigation to which we are a
party, the terms and conditions of our equity compensation plans, the impact of
insurance coverage, the enforceability of our patents, the loss of key
employees, the impact of compounding pharmacies, and generic products, our
beliefs regarding our recent merger with Sirius Laboratories, Inc. and the
benefits, effects, impact and risks thereof, our goal of achieving
profitability, our beliefs regarding our sales and marketing efforts,
competition with other companies, the adoption of our products, and the outcome
of such efforts, our beliefs regarding the use of our products and technologies
by third parties, our beliefs regarding our compliance with applicable laws,
rules and regulations, our beliefs regarding available reimbursement for our
products and changes to applicable CPT codes, our expectation regarding the
margins on our products, our beliefs regarding the current and future clinical
development and testing of our potential products and technologies and the costs
thereof, our expectations and beliefs regarding our future expenses and losses,
the sufficiency of our capital resources and our needs for additional capital,
the volatility of our stock price, our plans for obtaining financing in the
future and for pursuing certain goals and objectives, and the impact of our
rights plan, the possibility of the holders of options and warrants to purchase
our common stock exercising these securities.
You should read and interpret any forward-looking statements together with
the following documents:
- our most recent Annual Report on Form 10-K;
13
- our most recent Quarterly Report on Form 10-Q;
- the risk factors contained in this prospectus under the caption
"Risk Factors"; and
- our other filings with the Securities and Exchange Commission.
Any forward-looking statement speaks only as of the date on which that
statement is made. We will not update any forward-looking statement to reflect
events or circumstances that occur after the date on which such statement is
made.
USE OF PROCEEDS
We will not receive any proceeds from the sale of shares of common stock by
the Selling Shareholders.
The Selling Shareholders will pay any underwriting discounts and
commissions and expenses incurred by the Selling Shareholders for brokerage,
accounting, tax or legal services or any other expenses incurred by the Selling
Shareholders in disposing of the shares. We will bear all other costs, fees and
expenses incurred in effecting the registration of the shares covered by this
prospectus, including, without limitation, all registration and filing fees, and
fees and expenses of our counsel and our accountants.
SELLING SHAREHOLDERS
The Selling Shareholders acquired the shares held by them and offered by
this prospectus in connection with our acquisition of Sirius Laboratories, Inc.
On March 10, 2006, we entered into a merger agreement, as amended, with Sirius,
DUSA Acquisition Corp., or Merger Sub, and certain shareholders of Sirius, and
an accompanying plan of merger. The merger agreement provides for, among other
things, the merger of Sirius with and into the Merger Sub pursuant to which
Merger Sub became a wholly-owned subsidiary of our company. Under the merger
agreement, we agreed to pay $8,000,000 in cash and issue shares of our common
stock based on a formula as consideration for the purchase of all of the
outstanding shares of Sirius. In addition, we agreed to pay up to an additional
$5,000,000, of which $1,500,000 may be paid in cash and $3,500,000 may be paid
in either cash or shares of our common stock, at our sole discretion, if certain
new product approvals or launches are achieved or upon the achievement of
certain pre-determined total cumulative sales milestones for Sirius products
over a 42-month period beginning March 10, 2006. The transaction closed on March
10, 2006, and we issued at closing an aggregate of 2,396,245 shares of our
common stock to the former stockholders and option holders of Sirius as
consideration for the merger, some of which are held in escrow.
In accordance with the merger agreement, an aggregate of 422,892 shares of
our common stock were delivered into an indemnification escrow subject to the
terms of an escrow agreement dated March 10, 2006. These escrowed shares are
registered under the registration statement of which this prospectus forms a
part and accordingly are covered by this prospectus. However, the Selling
Shareholders will not have the right to sell the escrowed shares until they are
released pursuant to the terms of the escrow agreement. Any shares we issue as
part of the achievement of the milestones are not registered under the
registration statement of which this prospectus forms a part and are not covered
by this prospectus. Any shares issued as part of a milestone payment may be
registered under an additional registration statement prepared and filed by us
to cover such shares.
This prospectus also covers any additional shares of common stock which
become issuable in connection with the shares being registered by reason of any
stock dividend, stock split, recapitalization or other similar transaction
effected without the receipt of consideration which results in an increase in
the number of our outstanding shares of common stock.
The issuance of the such shares was exempt from the registration
requirements of the Securities Act, pursuant to Section 4(2) thereof and
Regulation D promulgated thereunder, based in part upon representations that we
obtained from each Selling Shareholder that such person is an "accredited
investor" or had a "purchaser representative" as such terms are defined in Rule
501 of Regulation D. Furthermore, in connection with the merger, certain of the
shares of our common stock were issued to a Selling Shareholder that is a
corporation organized under
14
the laws of the United Kingdom, in reliance upon the provisions of Regulation S
promulgated under the Securities Act. We are registering the shares of common
stock in order to permit the Selling Shareholders to offer the shares for resale
from time to time. Except as indicated in this section, we are not aware of any
material relationship between us and the Selling Shareholders within the past
three years, other than as a result of the Selling Shareholders' beneficial
ownership of our common stock or as a result of their employment with us as of
the date of the closing of the merger.
The table below lists the Selling Shareholders and, to our knowledge, other
information regarding the beneficial ownership of shares of our common stock by
each of the Selling Shareholders as of June 1, 2006 or as of March 10, 2006.
Beneficial ownership is determined in accordance with the rules and regulations
of the SEC, and includes voting or investment power with respect to these
shares. Unless otherwise indicated below, to our knowledge, all persons named in
the table have sole voting and investment power with respect to their shares of
common stock, except to the extent authority is shared by spouses under
applicable law. The inclusion of any shares in this table does not constitute an
admission of beneficial ownership for the persons named below.
The first column lists the number of shares of common stock beneficially
owned by each Selling Shareholder, based on his, her or its ownership of shares
of common stock. The second column lists the shares of common stock being
offered by this prospectus by the Selling Shareholders. The third column assumes
the sale of all of the shares of common stock offered by the Selling
Shareholders pursuant to this prospectus.
According to the terms of the merger agreement, the shares set forth below
are subject to certain restrictions on transfer, as described herein under the
section entitled "Plan of Distribution." The number of shares in the third
column does not reflect this limitation. The Selling Shareholders may sell all,
some or none of their shares in this offering. See "Plan of Distribution."
The information set forth below is based upon information obtained from the
Selling Shareholders and upon information in our possession regarding the
issuance of securities to the Selling Shareholders in connection with the
merger.
15
SHARES BENEFICIALLY OWNED NUMBER OF SHARES SHARES BENEFICIALLY OWNED
PRIOR TO OFFERING OFFERED PURSUANT AFTER OFFERING
------------------------- TO THIS -------------------------
NAME NUMBER PERCENTAGE (1) PROSPECTUS (2) (3) NUMBER PERCENTAGE (1)
---- ------ -------------- ------------------ ------ --------------
Frank R. Pollard and Jean E. Pollard
(4) 604,323 3.10 604,323 0 0
Jeffrey R. Bernstein (5) 370,191 1.90 370,191 0 0
Carole Bernstein (6) 270,612 1.39 270,612 0 0
Joel Bernstein (7) 195,511 1.00 195,511 0 0
Bioglan Pharma PLC (8) 107,835 * 107,835 0 0
David Bernstein (9) 90,203 * 90,203 0 0
Rebecca Zelken (9) 90,203 * 90,203 0 0
Frank R. Pollard, Jr. (10) 53,322 * 53,322 0 0
Scott E. Pollard (10) 53,322 * 53,322 0 0
Brett A. Pollard (10) 53,322 * 53,322 0 0
Keyoumars Soltani (11) 46,333 * 46,333 0 0
Saeed Soltani (12) 7,617 * 7,617 0 0
David Whitney (10) 53,322 * 53,322 0 0
Garry R. Barnes and Luanna Barnes
(13) 94,691 * 94,691 0 0
Madkat Capital Ventures, LLC (14) 17,774 * 17,774 0 0
Stephen M. Harrison and Stephen M.
Harrison Revocable Trust (15) 17,774 * 17,774 0 0
John Robert Hamill, Jr. (16) 10,664 * 10,664 0 0
Neal Penneys and Annette Friend (17) 22,450 * 22,450 0 0
William H. Eaglstein (18) 9,828 * 9,828 0 0
Ronald Sandler and Andrea Sandler
(19) 8,886 * 8,886 0 0
Alan Shalita and Simone Shalita (20) 9,514 * 9,514 0 0
Lawrence E. Levine (21) 21,438 * 21,438 0 0
Stephen Mandy (22) 22,243 * 22,243 0 0
Paul Marsh (23) 6,285 * 6,285 0 0
Maibach Trust and Howard Maibach (24) 6,180 * 6,180 0 0
Gerald R. McCluskey (25) 3,999 * 3,999 0 0
Esther Levine and Sidney Levine (26) 3,554 * 3,554 0 0
Robert Yolles and Monica Yolles (26) 3,554 * 3,554 0 0
Andrew Kaplan (27) 3,064 * 3,064 0 0
Jeffrey Kaplan (28) 2,357 * 2,357 0 0
Betty Lichter (29) 1,777 * 1,777 0 0
John Redfield and Pamela Redfield
(29) 1,777 * 1,777 0 0
Lawrence Peter Yolles (29) 1,777 * 1,777 0 0
Robert Andrew Yolles and Meredith
Yolles (29) 1,777 * 1,777 0 0
Anita Gerber (30) 1,746 * 1,746 0 0
Joseph John Yolles (31) 1,571 * 1,571 0 0
Harvey Herman and Cindy Herman (32) 888 * 888 0 0
Arona Roshal (33) 872 * 872 0 0
Mara Roshal (33) 872 * 872 0 0
Kristin Rasmussen (34) 622 * 622 0 0
Frank Kern (35) 355 * 355 0 0
Erik Anderson (36) 1,047 * 1,047 0 0
Patrick Bance (37) 1,676 * 1,676 0 0
Barbara Barnett (31) 1,571 * 1,571 0 0
Ronald Bruns (38) 23,049 * 23,049 0 0
Chris Buchinski (31) 1,571 * 1,571 0 0
16
SHARES BENEFICIALLY OWNED NUMBER OF SHARES SHARES BENEFICIALLY OWNED
PRIOR TO OFFERING OFFERED PURSUANT AFTER OFFERING
------------------------- TO THIS -------------------------
NAME NUMBER PERCENTAGE (1) PROSPECTUS (2) (3) NUMBER PERCENTAGE (1)
---- ------ -------------- ------------------ ------ --------------
Laura Butkus (39) 1,099 * 1,099 0 0
Rich Clements (31) 1,571 * 1,571 0 0
Tiffany Hagerty (31) 1,571 * 1,571 0 0
Jennifer Hoscheid (31) 1,571 * 1,571 0 0
Alan Kapuschinsky (40) 4,400 * 4,400 0 0
Andrea Maurer (36) 1,047 * 1,047 0 0
Matt Mitchell (36) 1,047 * 1,047 0 0
Jerry Osterman (41) 4,191 * 4,191 0 0
Dennis Peeler (42) 3,143 * 3,143 0 0
Ryan Reed (43) 4,085 * 4,085 0 0
Dominique Sanders (36) 1,047 * 1,047 0 0
Tim Schneider (44) 10,477 * 10,477 0 0
Antonia Vivian (45) 1,257 * 1,257 0 0
Michelle Willman (46) 3,143 * 3,143 0 0
Frederick Siegel (36) 1,047 * 1,047 0 0
Scott Phillips (47) 2,043 * 2,043 0 0
James Demas (31) 1,571 * 1,571 0 0
Stephen Schwartz (48) 8,905 * 8,905 0 0
Ahnal Purohit (49) 2,095 * 2,095 0 0
Cheryl Ackerman (50) 209 * 209 0 0
Jeffrey Alter (51) 313 * 313 0 0
David Arluk (51) 313 * 313 0 0
Anthony Aulisio (50) 209 * 209 0 0
Aurora Badia (50) 209 * 209 0 0
Jacob Baral (51) 313 * 313 0 0
Kenneth Beer (51) 313 * 313 0 0
Michael Bell (51) 313 * 313 0 0
Richard Berry (50) 209 * 209 0 0
Harris Blackman (50) 209 * 209 0 0
Mitchell Bressack (50) 209 * 209 0 0
Solomon Brickman (51) 313 * 313 0 0
Robert Brodell (51) 313 * 313 0 0
Darryl Bronson (51) 313 * 313 0 0
Ligaya Buchbinder (51) 313 * 313 0 0
Harry Burglass (50) 209 * 209 0 0
Jeffrey Callen (50) 209 * 209 0 0
Joseph Cavallo (51) 313 * 313 0 0
Scott Checketts (51) 313 * 313 0 0
Larry Cole (51) 313 * 313 0 0
Michael Cormier (51) 313 * 313 0 0
David Coynik (50) 209 * 209 0 0
Jonathan Crane (51) 313 * 313 0 0
Judith Crowell (50) 209 * 209 0 0
Ronald Daigle (50) 209 * 209 0 0
Theodore Daly (50) 209 * 209 0 0
Kenneth Dawes (50) 209 * 209 0 0
Frank DeMento (51) 313 * 313 0 0
Karen Devore (50) 209 * 209 0 0
Kenneth Dorsey (50) 209 * 209 0 0
William Doubleday (51) 313 * 313 0 0
Michael Doucet (51) 313 * 313 0 0
Drore Eisen (50) 209 * 209 0 0
Richard Eisenberg (50) 209 * 209 0 0
Lester Fahrner (51) 313 * 313 0 0
Mark Fairhurst (50) 209 * 209 0 0
Ronald Falcon (51) 313 * 313 0 0
17
SHARES BENEFICIALLY OWNED NUMBER OF SHARES SHARES BENEFICIALLY OWNED
PRIOR TO OFFERING OFFERED PURSUANT AFTER OFFERING
------------------------- TO THIS -------------------------
NAME NUMBER PERCENTAGE (1) PROSPECTUS (2) (3) NUMBER PERCENTAGE (1)
---- ------ -------------- ------------------ ------ --------------
Michael Fisher (50) 209 * 209 0 0
Scott Fretzin (50) 209 * 209 0 0
Barry Galitzer (51) 313 * 313 0 0
A. John Ghorbani (50) 209 * 209 0 0
Scott Glazer (51) 313 * 313 0 0
Brad Glick (51) 313 * 313 0 0
Michael Gold (51) 313 * 313 0 0
Michael T. Goldfarb, M.D. (50) 209 * 209 0 0
Mitch Goldman (51) 313 * 313 0 0
Leslie Gray (51) 313 * 313 0 0
Howard Green (50) 209 * 209 0 0
Steven Grekin (51) 313 * 313 0 0
Dina Grice (50) 209 * 209 0 0
Robert Grieshaber (50) 209 * 209 0 0
Michael Haag (51) 313 * 313 0 0
Gary Hahn (50) 209 * 209 0 0
Fred Hamaty (50) 209 * 209 0 0
Mark Hatch (50) 209 * 209 0 0
Herbert Hochman (51) 313 * 313 0 0
David Horowitz (51) 313 * 313 0 0
Nancy Howanitz (50) 209 * 209 0 0
Donald Iden (50) 209 * 209 0 0
Pierre Jaffe (50) 209 * 209 0 0
Lee Jordan (50) 209 * 209 0 0
Juana Julien (51) 313 * 313 0 0
Scott Kasteler (50) 209 * 209 0 0
Roderick Kauffmann (50) 209 * 209 0 0
Elena Kendall (50) 209 * 209 0 0
Andrew King (51) 313 * 313 0 0
Jean Kois (50) 209 * 209 0 0
Glenn Kolansky (50) 209 * 209 0 0
Bruce Kolton (50) 209 * 209 0 0
Rene Koppel (50) 209 * 209 0 0
Keith Kozeny (51) 313 * 313 0 0
Margaret Lally (50) 209 * 209 0 0
Alan Lasser (50) 209 * 209 0 0
Andrew Lazar (50) 209 * 209 0 0
Seth Lerner (50) 209 * 209 0 0
David Levine (50) 209 * 209 0 0
Tehming Liang (50) 209 * 209 0 0
Patrick Lillis (50) 209 * 209 0 0
Deborah Longwill (51) 313 * 313 0 0
Emmanuel Loucas (51) 313 * 313 0 0
Michael Maloney (51) 313 * 313 0 0
Eugene Mandrea (51) 313 * 313 0 0
Richard Mayron (50) 209 * 209 0 0
Lisa Meils (50) 209 * 209 0 0
Ricardo Mejia (50) 209 * 209 0 0
Chanachai Memark (50) 209 * 209 0 0
Sharon Meyer (51) 313 * 313 0 0
Craig Mohney (50) 209 * 209 0 0
William Moores (50) 209 * 209 0 0
Eliot Mostow (50) 209 * 209 0 0
Steven Musick (50) 209 * 209 0 0
George Nahass (50) 209 * 209 0 0
Joseph Newmark (50) 209 * 209 0 0
18
SHARES BENEFICIALLY OWNED NUMBER OF SHARES SHARES BENEFICIALLY OWNED
PRIOR TO OFFERING OFFERED PURSUANT AFTER OFFERING
------------------------- TO THIS -------------------------
NAME NUMBER PERCENTAGE (1) PROSPECTUS (2) (3) NUMBER PERCENTAGE (1)
---- ------ -------------- ------------------ ------ --------------
Neil Niren (51) 313 * 313 0 0
John Niven (50) 209 * 209 0 0
Michael Noonan (50) 209 * 209 0 0
Mark Oestreicher (51) 313 * 313 0 0
William O'Grady (50) 209 * 209 0 0
Robert Orme (51) 313 * 313 0 0
Paul Orton (51) 313 * 313 0 0
Rube Pardo (50) 209 * 209 0 0
Arun Pathy (50) 209 * 209 0 0
Robert Paull (51) 313 * 313 0 0
Patricia Peeples Westmoreland (51) 313 * 313 0 0
Nina Petroff (50) 209 * 209 0 0
Ira Pion (50) 209 * 209 0 0
George Poche (50) 209 * 209 0 0
Wayne Porter (51) 313 * 313 0 0
Douglas Pravda (51) 313 * 313 0 0
Mark Quarterman (51) 313 * 313 0 0
Virginia Rae (50) 209 * 209 0 0
Charles Reed (51) 313 * 313 0 0
Marta Rendon (51) 313 * 313 0 0
Barry Resnik (51) 313 * 313 0 0
Paul Revis (51) 313 * 313 0 0
Tobi Richman (51) 313 * 313 0 0
Lawrence Rivkin (50) 209 * 209 0 0
William Roth (51) 313 * 313 0 0
Gordon Russo (51) 313 * 313 0 0
Gabrielle Sabini (50) 209 * 209 0 0
Jeffrey Schachne (50) 209 * 209 0 0
Scott Schafrank (50) 209 * 209 0 0
Andrew Scheman (50) 209 * 209 0 0
Martin Schiff (50) 209 * 209 0 0
Stanley Schnall (50) 209 * 209 0 0
David Schulman (51) 313 * 313 0 0
Stanley Schwartz (50) 209 * 209 0 0
David Semler (50) 209 * 209 0 0
Mark Seraly (50) 209 * 209 0 0
Steven Shapiro (50) 209 * 209 0 0
Michael Siegel (50) 209 * 209 0 0
Salma Simjee (50) 209 * 209 0 0
Jeffrey Sklar (50) 209 * 209 0 0
Barry Solomon (50) 209 * 209 0 0
Neal Spero (50) 209 * 209 0 0
Ronald Spillane (51) 313 * 313 0 0
Philip Strenger (50) 209 * 209 0 0
Joseph Sutton (50) 209 * 209 0 0
Craig Teller (51) 313 * 313 0 0
David Van Dam (51) 313 * 313 0 0
Ted Vanacker (51) 313 * 313 0 0
Bruce Warshauer (51) 313 * 313 0 0
Seymour Weaver (50) 209 * 209 0 0
Lawrence Wells (50) 209 * 209 0 0
Stuart Wernikoff (50) 209 * 209 0 0
Morris Westfried (50) 209 * 209 0 0
Hector Wiltz (51) 313 * 313 0 0
Peter Winters (50) 209 * 209 0 0
James Yeckley (50) 209 * 209 0 0
19
SHARES BENEFICIALLY OWNED NUMBER OF SHARES SHARES BENEFICIALLY OWNED
PRIOR TO OFFERING OFFERED PURSUANT AFTER OFFERING
------------------------- TO THIS -------------------------
NAME NUMBER PERCENTAGE (1) PROSPECTUS (2) (3) NUMBER PERCENTAGE (1)
---- ------ -------------- ------------------ ------ --------------
Cheuk Yung (50) 209 * 209 0 0
* Indicates less than 1%.
(1) Based upon 19,469,442 shares of common stock outstanding as of June 1,
2006. For the purposes of computing the percentage of outstanding shares of
common stock held by each Selling Shareholder named above, any shares which
the Selling Shareholder has the right to acquire within 60 days of June 1,
2006, are deemed to be outstanding but are not deemed to be outstanding for
the purpose of computing the percentage ownership of any other Selling
Shareholder.
(2) We do not know when or in what amounts a Selling Shareholder may offer
shares for sale. The Selling Shareholders might not sell any or all of the
shares offered by this prospectus. Because the Selling Shareholders may
offer all or some of the shares in this offering, and because there are
currently no agreements, arrangements or understandings concerning the sale
of any of the shares, we cannot estimate the number of the shares that will
be held by the Selling Shareholders after completion of the offering.
However, for purposes of this table, we have assumed that, after completion
of the offering, none of the shares covered by this prospectus will be held
by the Selling Shareholders.
(3) Pursuant to the terms of the merger agreement, the Shareholder
Representatives (as defined in the merger agreement) have voting control
over the 422,892 shares of common stock held in escrow. However, for
purposes of determining beneficial ownership hereunder, each Selling
Shareholder is deemed to have beneficial ownership of such shares of common
stock allocable to him, her or it which are being held in escrow.
(4) Such shares are held jointly and include 106,645 shares held in escrow. Mr.
Pollard is a part-time consultant to DUSA.
(5) Includes 65,328 shares held in escrow.
(6) Includes 47,755 shares held in escrow. Carole Bernstein is married to Joel
Bernstein and may be deemed to beneficially own his shares.
(7) Includes 34,502 shares held in escrow. Joel Bernstein is married to Carole
Bernstein and may be deemed to beneficially own her shares.
(8) Includes 19,030 shares held in escrow.
(9) Includes 15,918 shares held in escrow.
(10) Includes 9,410 shares held in escrow.
(11) Includes 8,177 shares held in escrow.
(12) Includes 1,344 shares held in escrow.
(13) Of such shares, 47,545 are held jointly. Includes 16,710 shares held in
escrow.
(14) Includes 3,137 shares held in escrow.
(15) Includes 3,137 shares held in escrow.
(16) Includes 1,882 shares held in escrow.
(17) Of such shares, 10,664 are held jointly. Includes 3,962 shares held in
escrow. Dr. Penneys is a director of DUSA under the terms of the merger.
(18) Includes 1,734 shares held in escrow.
(19) Such shares are held jointly. Includes 1,568 shares held in escrow.
(20) Of such shares, 8,886 are held jointly. Includes 1,679 shares held in
escrow.
(21) Includes 3,783 shares held in escrow.
(22) Includes 3,925 shares held in escrow.
(23) Includes 1,109 shares held in escrow.
(24) Of such shares, 5,238 are held in the name of the Maibach Trust. Includes
1,090 shares held in escrow.
(25) Includes 706 shares held in escrow.
(26) Includes 627 shares held in escrow.
20
(27) Includes 541 shares held in escrow.
(28) Includes 416 shares held in escrow.
(29) Includes 314 shares held in escrow.
(30) Includes 308 shares held in escrow.
(31) Includes 277 shares held in escrow.
(32) Includes 157 shares held in escrow.
(33) Includes 154 shares held in escrow.
(34) Includes 110 shares held in escrow.
(35) Includes 63 shares held in escrow.
(36) Includes 185 shares held in escrow.
(37) Includes 296 shares held in escrow.
(38) Includes 4,068 shares held in escrow.
(39) Includes 194 shares held in escrow.
(40) Includes 777 shares held in escrow.
(41) Includes 740 shares held in escrow.
(42) Includes 555 shares held in escrow.
(43) Includes 721 shares held in escrow.
(44) Includes 1,849 shares held in escrow.
(45) Includes 222 shares held in escrow.
(46) Includes 555 shares held in escrow.
(47) Includes 361 shares held in escrow.
(48) Includes 1,572 shares held in escrow.
(49) Includes 370 shares held in escrow.
(50) Includes 37 shares held in escrow.
(51) Includes 55 shares held in escrow.
21
PLAN OF DISTRIBUTION
The Selling Shareholders may, from time to time, after the expiration of
the lock-up period applicable to them, sell some or all of their shares of
common stock issued pursuant to the merger agreement on any stock exchange,
market or trading facility on which the shares are traded or in private
transactions. These sales may be at fixed or negotiated prices. The Selling
Shareholders may use any one or more of the following methods when Selling
Shares: ordinary brokerage transactions and transactions in which the
broker-dealer solicits purchasers; block trades in which the broker-dealer will
attempt to sell the shares as agent but may position and resell a portion of the
block as principal to facilitate the transaction; purchases by a broker-dealer
as principal and resale by the broker-dealer for its account; an exchange
distribution in accordance with the rules of the applicable exchange; privately
negotiated transactions; short sales; broker-dealers may agree with the Selling
Shareholders to sell a specified number of such shares at a stipulated price per
share; a combination of any such methods of sale; and any other method permitted
pursuant to applicable law.
The Selling Shareholders may sell shares under Rule 144 under the
Securities Act, if available, rather than under this prospectus.
The Selling Shareholders may also subject to restrictions in the merger
agreement, engage in short sales against the box, puts and calls and other
transactions in our securities or derivatives of our securities and may sell or
deliver shares in connection with these trades. The Selling Shareholders may
also enter into hedging transactions with broker-dealers in connection with
distributions of their shares or otherwise. In such transactions, broker-dealers
may engage in short sales of the shares in the course of hedging the positions
they assume with any Selling Shareholder. The Selling Shareholders also may sell
shares short and redeliver the shares to close out such short positions. The
Selling Shareholders may also enter into option or other transactions with
broker-dealers or other financial institutions or the creation of one or more
derivative securities which require the delivery to such broker-dealer or other
financial institution of shares offered by this prospectus, which shares such
broker-dealer or other financial institution may resell pursuant to this
prospectus (as supplemented or amended to reflect such transaction). The Selling
Shareholders also may loan or pledge their shares to a broker-dealer. The
broker-dealer may sell the shares so loaned, or upon a default the broker-dealer
or other financial institution may sell the pledged shares under this prospectus
(as supplemented or amended to reflect such transaction).
Broker-dealers engaged by the Selling Shareholders may arrange for other
brokers-dealers to participate in sales. Broker-dealers may receive commissions
or discounts from the Selling Shareholders (or, if any broker-dealer acts as
agent for the purchaser of shares, from the purchaser) in amounts to be
negotiated. The Selling Shareholders do not expect these commissions and
discounts to exceed what is customary in the types of transactions involved. Any
profits on the resale of shares of common stock by a broker-dealer acting as
principal might be deemed to be underwriting discounts or commissions under the
Securities Act. Discounts, concessions, commissions and similar selling
expenses, if any, attributable to the sale of shares will be borne by a Selling
Shareholders. The Selling Shareholders may agree to indemnify any agent, dealer
or broker-dealer that participates in transactions involving sales of the shares
if liabilities are imposed on that person under the Securities Act.
The Selling Shareholders may from time to time pledge or grant a security
interest in some or all of the shares of common stock owned by them and, if they
default in the performance of their secured obligations, the pledgees or secured
parties may offer and sell the shares of common stock from time to time under
this prospectus after we have filed an amendment to this prospectus under Rule
424(b)(3) or other applicable provision of the Securities Act of 1933 amending
the list of Selling Shareholders to include the pledgee, transferee or other
successors in interest as Selling Shareholders under this prospectus.
Notwithstanding registration of the shares of common stock under the
registration statement, such shares are subject to additional restrictions on
transfer, as set forth in the merger agreement. The shares of our common stock
issued in connection with the merger to any Selling Shareholder who owned
directly or beneficially five percent (5%) or more of the issued and outstanding
shares of Sirius stock prior to the merger, is subject to a lock-up of the
shares of our common stock issued in the merger. Such shares are held in escrow
with fifty percent (50%) of such shares being released on the first anniversary
of the date of closing and the balance being released on the second anniversary
of the date of closing, unless earlier terminated pursuant to the terms of the
merger agreement.
In addition, each other Selling Shareholder has agreed to be subject to a
lock-up of their shares of our common stock until the earlier of the first
anniversary of the date of closing, or the date on which certain estimated
22
financial information is announced to the public by us or such information is
deemed by us, in our reasonable discretion, (in which case we will so notify
such locked-up Selling Shareholders) to be no longer material to the business
and operations of DUSA.
The Selling Shareholders also may transfer the shares of common stock in
other circumstances, in which case the transferees, pledgees or other successors
in interest will be the selling beneficial owners for purposes of this
prospectus and may sell the shares of common stock from time to time under this
prospectus after we have filed an amendment to this prospectus under Rule
424(b)(3) or other applicable provision of the Securities Act of 1933 amending
the list of Selling Shareholders to include the pledgee, transferee or other
successors in interest as Selling Shareholders under this prospectus.
The Selling Shareholders and any broker-dealers or agents that are involved
in selling the shares of common stock may be deemed to be "underwriters" within
the meaning of the Securities Act in connection with such sales. In such event,
any commissions received by such broker-dealers or agents and any profit on the
resale of the shares of common stock purchased by them may be deemed to be
underwriting commissions or discounts under the Securities Act. The Selling
Shareholders have advised us that they have acquired their securities in the
ordinary course of business and they have not entered into any agreements,
understandings or arrangements with any underwriters or broker-dealers regarding
the sale of their shares of common stock, nor is there an underwriter or
coordinating broker acting in connection with a proposed sale of shares of
common stock by any Selling Shareholders. If we are notified by any Selling
Shareholders that any material arrangement has been entered into with a
broker-dealer for the sale of shares of common stock, if required, we will file
a supplement to this prospectus. If the Selling Shareholders use this prospectus
for any sale of the shares of common stock, they will be subject to the
prospectus delivery requirements of the Securities Act.
DUSA is required to pay all fees and expenses relating to the registration
of the shares of common stock. Subject to the terms and conditions set forth in
the registration rights agreement by and among DUSA and the shareholders of
Sirius Laboratories, Inc., DUSA has agreed to indemnify the Participating
Shareholders (as defined therein) against certain losses, claims, damages or
liabilities, including reasonable attorneys' fees, including liabilities under
the Securities Act of 1933, as amended.
The anti-manipulation rules of Regulation M under the Securities Exchange
Act of 1934 may apply to sales of our common stock and activities of the Selling
Shareholders.
LEGAL MATTERS
The validity of the shares being offered hereby will be passed upon for
DUSA by Reed Smith LLP.
EXPERTS
The financial statements and management's report on the effectiveness of
internal control over financial reporting incorporated in this prospectus by
reference from DUSA's Annual Report on Form 10-K for the year ended December 31,
2005 have been audited by Deloitte & Touche LLP, an independent registered
public accounting firm, as stated in their reports, which are incorporated
herein by reference, and have been so incorporated in reliance upon the reports
of such firm given upon their authority as experts in accounting and auditing.
In addition, the financial statements of Sirius Laboratories, Inc. for the
year ended December 31, 2005 incorporated by reference in this prospectus have
been audited by Altschuler, Melvoin and Glasser LLP, an independent registered
public accounting firm, as stated in their report, which is incorporated herein
by reference, and has been so incorporated in reliance upon their authority as
experts in accounting and auditing.
WHERE YOU CAN FIND MORE INFORMATION
We file annual, quarterly and current reports, proxy statements and other
information with the Securities and Exchange Commission in Washington, D.C. You
may read and copy any document we file at the SEC's public reference facilities
maintained by the SEC at Room 1024, 450 Fifth Street, NW, Washington, D.C.,
20549. The SEC has prescribed rates for copying. Please call the SEC at
1-800-SEC-0330 for further information on the public
23
reference room. Our SEC filings are also available to the public at the SEC's
website at http://www.sec.gov. Our filings are also available at our website at
http://www.dusapharma.com, which is not a part of this prospectus and is not
incorporated herein by reference.
Our reports and other information can also be inspected at the offices of
the National Association of Securities Dealers at 1735 K Street, NW, Washington,
DC 20006-1506.
INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
The following documents, which have been filed by us with the Commission
pursuant to the Securities Exchange Act of 1934, as amended, are incorporated by
reference in this registration statement as of their respective dates:
- Our Annual report on Form 10-K for the year ended December 31,
2005;
- Our Quarterly Reports on Form 10-Q for the periods ended March
31, 2006 and June 30, 2006;
- Our Current Reports on Form 8-K filed with the Commission on July
11, 2006, June 21, 2006, June 16, 2006, June 8, 2006, June 2,
2006, May 16, 2006, April 25, 2006, April 10, 2006, March 31,
2006, March 29, 2006, March 14, 2006, February 24, 2006, February
21, 2006, February 9, 2006, February 6, 2006, February 1, 2006,
January 23, 2006, January 18, 2006 and January 4, 2006;
- Our Current Reports on Form 8-K/A filed with the Commission on
August 15, 2006, June 7, 2006, and May 9, 2006;
- All other reports filed pursuant to Section 13 or 15(d) of the
Exchange Act since December 31, 2005; and
- The description of DUSA's common stock contained in its
registration statement on Form 8-A which was filed on January 3,
1992 and amended on Form 8-A12G filed on October 24, 1997, and in
DUSA's report on Form 10-Q which was filed on November 12, 1997.
All documents filed by us pursuant to Section 13(a), 13(c), 14 and 15(d) of
the Exchange Act after the date hereof and prior to the termination of the
offering shall be deemed to be incorporated by reference into this registration
statement and to be a part hereof from the date of filing of such documents. Any
statement contained in a document incorporated or deemed to be incorporated
herein by reference shall be deemed to be modified or superseded for purposes of
this prospectus to the extent that a statement contained herein or in any other
subsequently filed document which also is or is deemed to be incorporated by
reference herein modifies or supersedes such statement.
We will provide each person, including any beneficial owner, to whom a
prospectus is delivered, a copy of any or all of the information that has been
incorporated by reference in this prospectus, but not delivered with this
prospectus. We will provide such copies at no cost, upon written or oral
request, by writing or telephoning us at:
DUSA PHARMACEUTICALS, INC.
555 RICHMOND STREET WEST
SUITE 300, P.O. BOX 704
TORONTO, ONTARIO, CANADA
M5V 3B1
ATTENTION: MS. SHARI LOVELL
TELEPHONE: (800) 607-2530
E-MAIL TO: LOVELLS@DUSAPHARMA.COM
We maintain a world wide website, located at www.dusapharma.com.
Information on the website is not incorporated by reference into this
prospectus.
24
This prospectus is part of a registration statement on Form S-3 that we
filed with the SEC. You should rely only on the information and representations
provided in this prospectus or on the information incorporated by reference in
this prospectus. Neither we nor the Selling Shareholders have authorized anyone
to provide you with different information. Neither we nor the Selling
Shareholders are making an offer of these securities in any state where the
offer is not permitted. You should not assume that the information in this
prospectus is accurate as of any date other than the date on the front of this
document.
25
================================================================================
2,396,245 SHARES
DUSA
PHARMACEUTICALS, INC.
Common Stock
PROSPECTUS
August __, 2006
================================================================================
26
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
Item 14. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION
The following sets forth the expenses (excluding placement agent fees and
commissions) incurred in connection with the offering described in the
registration statement, all of which will be borne by DUSA.
SEC Registration Fee $ 1,233
NASDAQ Listing Fee -0-
Printing and Engraving* 1,000
Accounting Fees and Expenses* 30,000
Legal Fees and Expenses 30,000
Miscellaneous Expenses* 5,000
-------
TOTAL $67,233
=======
* Estimated.
Item 15. INDEMNIFICATION OF DIRECTORS AND OFFICERS
Article 5 of the Company's Certificate of Incorporation, as amended, and
New Jersey Business Corporation Act, N.J.S.A. 14A:2-7 provide as follows:
Any director and officer of the Corporation shall not be personally liable
to the Corporation or its shareholders for damages for breach of any duty
owed to the Corporation or its shareholders, except that this provision
shall not relieve a director or officer from liability for any breach of
duty based upon an act or omission (a) in breach of such person's duty of
loyalty to the Corporation or its shareholders; (b) not in good faith or
involving a knowing violation of law; or (c) resulting in receipt by such
person of an improper personal benefit.
The Company's By-laws, as amended, pursuant to the New Jersey Business
Corporation Act, N.J.S.A. 14A:3-5, provide as follows:
ARTICLE IV
INDEMNIFICATION
Section 1. Actions by Others. The Corporation (1) shall indemnify any
person who was or is a party or is threatened to be made a party to any
threatened, pending or completed action, suit or proceeding, whether civil,
criminal, administrative or investigative (other than an action by or in the
right of the Corporation) by reason of the fact that he is or was a director,
officer or trustee of the Corporation or of any constituent corporation absorbed
by the Corporation in a consolidation or merger and (2) except as otherwise
required by Section 3 of this Article, may indemnify any person who was or is a
party or is threatened to be made a party to any threatened, pending or
completed action, suit or proceeding, whether civil, criminal, administrative or
investigative (other than an action by or in the right of the Corporation) by
reason of the fact that he (a) is or was an employee or agent or the legal
representative of a director, officer, trustee, employee or agent of the
Corporation or of any absorbed constituent corporation, or (b) is or was serving
at the request of the Corporation or of any absorbed constituent corporation as
a director, officer, employee, agent of or participant in another corporation,
partnership, joint venture, trust or other enterprise, or the legal
representative of such a person against expenses, costs, disbursements
(including attorneys' fees), judgments, fines and amounts actually and
reasonably incurred by him in good faith and in connection with such action,
suit or proceeding if he acted in a manner he reasonably believed to be in or
not opposed to the best interests of the Corporation, and with respect to any
criminal action or proceeding, he had no reasonable cause to
II-1
believe that his conduct was unlawful. The termination of any action, suit or
proceeding by judgment, order, settlement, conviction, or upon a pleas of nolo
contendere or its equivalent, shall not, of itself, create a presumption that
the person did not meet the applicable standard of conduct.
Section 2. Actions by or in the Right of the Corporation. The Corporation
shall indemnify any person who was or is a party or is threatened to be made a
party to any threatened, pending or completed action or suit by or in the right
of the Corporation to procure a judgment in its favor by reason of the fact that
he is or was a director, officer, trustee, employee or agent of the Corporation
or of any constituent corporation absorbed by the Corporation by consolidation
or merger, or the legal representative of any such person, or is or was serving
at the request of the Corporation or of any absorbed constituent corporation, as
a director, officer, trustee, employee, agent of or participant, or the legal
representative of any such person in another corporation, partnership, joint
venture, trust or other enterprise against expenses (including attorneys' fees)
actually and reasonably incurred by him in connection with the defense or
settlement of such action or suit if he acted in good faith and in a manner he
reasonably believed to be in or not opposed to the best interests of the
Corporation and except that no indemnification shall be made in respect of any
claim, issue or matter as to which such person shall have been adjudged to be
liable to the Corporation unless and only to the extent that the New Jersey
Superior Court or the court in which such action or suit was brought shall
determine upon application that, despite the adjudication of liability but in
view of all the circumstances of the case, such person is fairly and reasonably
entitled to indemnity for such expenses which the New Jersey Superior Court or
such other court shall deem proper.
Section 3. Successful Defense. To the extent that a person who is or was a
director, officer, trustee, employee or agent of the Corporation or of any
constituent corporation absorbed by the Corporation by consolidation or merger,
or the legal representative of any such person, has been successful on the
merits or otherwise in defense of any action, suit or proceeding referred to in
Section 1 or Section 2 of this Article, or in defense of any claim, issue, or
matter therein, he shall be indemnified against expenses (including attorneys'
fees) actually and reasonably incurred by him in connection therewith.
Section 4. Specific Authorization. Any indemnification under Section 1 or
Section 2 of this Article (unless ordered by a court) shall be made by the
Corporation only as authorized in the specific case upon a determination that
indemnification of the director, officer, trustee, employee, agent, or the legal
representative thereof, is proper in the circumstances because he has met the
applicable standard of conduct set forth in said Sections 1 and 2. Such
determination shall be made (1) by the Board of Directors by a majority vote of
quorum consisting of directors who were not parties to such action, suit or
proceeding, or (2) if such a quorum is not obtainable, a quorum of disinterested
directors so directs, by independent legal counsel for a written opinion, (3) by
the shareholders.
Section 5. Advance of Expenses. Expenses incurred by any person who may
have a right of indemnification under this Article in defending civil or
criminal action, suit or proceeding may be paid by the Corporation in advance of
the final distribution of such action, suit or proceeding as authorized by the
board of directors upon receipt of an undertaking by or on behalf of the
director, officer, trustee, employee, or the legal representative thereof, to
repay such amount unless it shall ultimately be determined that he is entitled
to be indemnified by the Corporation pursuant to this Article.
Section 6. Right of Indemnity not Exclusive. The indemnification and
advancement of expenses provided by this Article shall not exclude any other
rights to which those seeking indemnification may be entitled under the
certificate of incorporation of the Corporation or any by-law, agreement, vote
of shareholders or otherwise; provided that no indemnification shall be made to
or on behalf of a Director, officer, trustee, employee, agent, or legal
representative if a judgment or other final adjudication adverse to such persons
establishes that his acts or omissions (a) were in breach of his duty of loyalty
to the corporation or its shareholders, (b) were not in good faith or involved a
knowing violation of law or (c) resulted in receipt by such person of an
improper personal benefit.
Section 7. Insurance. The Corporation may purchase and maintain insurance
on behalf of any person who is or was a director, officer, trustee, employee or
agent of the Corporation or of any constituent corporation absorbed by the
Corporation by consolidation or merger of the legal representative of such
person or is or was serving at the request of the Corporation or of any absorbed
constituent corporation as a director, officer,
II-2
trustee, employee or agent of or participant in another corporation,
partnership, joint venture, trust or other enterprise, or the legal
representative of any such person against any liability asserted against him and
incurred by him in any such capacity, arising out of his status as such or by
reason of his being or having been such, whether or not the Corporation would
have the power to indemnify him against such liability under the provisions of
this Article, the New Jersey Business Corporation Act, or otherwise.
Section 8. Invalidity of any Provision of this Article. The invalidity or
unenforceability of any provision of this Article shall not affect the validity
or enforceability of the remaining provisions of this Article.
II-3
Item 16. EXHIBITS
(a) Exhibits:
(2.1) Merger Agreement dated December 30, 2005, as amended, by and among
DUSA, Sirius Laboratories, Inc. and certain shareholders of Sirius.
Filed with the Securities and Exchange Commission on March 10, 2006
as Exhibit 2(a.1) to the Company's Annual Report on Form 10-K for the
period ended December 31, 2005, and incorporated herein by reference.
(4.1) Common Stock specimen, filed as Exhibit 4(a) to the Registrant's Form
10-K for the fiscal year ended December 31, 2002, and is incorporated
herein by reference.
(4.2) Rights Agreement filed as Exhibit 4.0 to Registrant's Current Report
on Form 8-K dated September 27, 2002, filed October 11, 2002, and is
incorporated herein by reference.
(4.3) Rights Certificate relating to the rights granted to holders of
common stock under the Rights Agreement filed as Exhibit 4.0 to
Registrant's Current Report on Form 8-K, dated September 27, 2002,
filed October 11, 2002, and is incorporated herein by reference.
(4.4) Registration Rights Agreement by and among DUSA and certain
shareholders of Sirius dated March 10, 2006, filed as Exhibit 4.1 to
the Registrant's Current Report on Form 8-K dated March 14, 2006, and
incorporated herein by reference.
(5.1) Opinion of Reed Smith LLP.
(23.1) Consent of Deloitte & Touche LLP.
(23.2) Consent of Altschuler, Melvoin and Glasser LLP.
(23.3) Consent of Reed Smith LLP.
(24.1) Power of Attorney appointing D. Geoffrey Shulman, MD, FRCPC and
Robert F. Doman on original signature page.
II-4
Item 17. UNDERTAKINGS
(a) The undersigned Registrant hereby undertakes:
(1) To file, during any period in which offers or sales are being made, a
post-effective amendment to this registration statement:
(i) To include in any prospectus required by Section 10(a)(3) of the
Securities Act of 1933;
(ii) To reflect in the prospectus any facts or events arising after
the effective date of this registration statement (or the most recent
post-effective amendment thereof) which, individually or in the
aggregate, represent a fundamental change in the information set forth
in this registration statement. Notwithstanding the foregoing, any
increase or decrease in volume of securities offered (if the total
dollar value of securities offered would not exceed that which was
registered) and any deviation from the low or high end of the
estimated maximum offering range may be reflected in the form of
prospectus filed with the Commission pursuant to Rule 424(b) if, in
the aggregate, the changes in volume and price represent no more than
a 20% change in the maximum offering price set forth in the
"Calculation of Registration Fee" table in the effective registration
statement;
(iii) To include any material information with respect to the plan of
distribution not previously disclosed in this registration statement
or any material change to such information in this registration
statement;
provided, however, that paragraphs (1)(i), (1)(ii) and (1)(iii) do not
apply if the information required to be included in a post-effective
amendment by those paragraphs is contained in periodic reports filed
by the Registrant pursuant to Section 13 or Section 15(d) of the
Securities Exchange Act of 1934, as amended, that are incorporated by
reference in this registration statement, or is contained in a form of
prospectus filed pursuant to Rule 424(b) that is part of this
registration statement.
(2) That, for the purpose of determining any liability under the Securities
Act of 1933, each such post-effective amendment shall be deemed to be a new
registration statement relating to the securities offered therein, and the
offering of such securities at that time shall be deemed to be the initial
bona fide offering thereof.
(3) To remove from registration by means of a post-effective amendment any
of the securities being registered which remain unsold at the termination
of the offering.
(4) That, for the purpose of determining liability under the Securities Act
of 1933 to any purchaser, each prospectus filed pursuant to Rule 424(b) as
part of a registration statement relating to an offering, other than
registration statements relying on Rule 430B or other than prospectuses
filed in reliance on Rule 430A, shall be deemed to be part of and included
in the registration statement as of the date it is first used after
effectiveness. Provided, however, that no statement made in a registration
statement or prospectus that is part of the registration statement or made
in a document incorporated or deemed incorporated by reference into the
registration statement or prospectus that is part of the registration
statement will, as to a purchaser with a time of contract of sale prior to
such first use, supersede or modify any statement that was made in the
registration statement or prospectus that was part of the registration
statement or made in any such document immediately prior to such date of
first use.
(5) The undersigned registrant hereby undertakes that, for purposes of
determining any liability under the Securities Act of 1933, each filing of
the registrant's annual report pursuant to section 13(a) or section 15(d)
of the Securities Exchange Act of 1934 (and, where applicable, each filing
of an employee benefit
II-5
plan's annual report pursuant to section 15(d) of the Securities Exchange
Act of 1934) that is incorporated by reference in the registration
statement shall be deemed to be a new registration statement relating to
the securities offered therein, and the offering of such securities at that
time shall be deemed to be the initial bona fide offering thereof.
II-6
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant
certifies that it has reasonable grounds to believe that it meets all of the
requirements for filing on Form S-3 and has duly caused this registration
statement to be signed on its behalf by the undersigned, thereunto duly
authorized, in the City of Wilmington, Commonwealth of Massachusetts, USA, on
August 15, 2006.
DUSA PHARMACEUTICALS, INC.
By: /s/ D. Geoffrey Shulman
-----------------------------------------
D. Geoffrey Shulman,
Chairman of the Board and Chief Executive
Officer
SIGNATURES AND POWER OF ATTORNEY
Know All Men By These Presents, that each person whose signature appears
below constitutes and appoints D. Geoffrey Shulman and Robert F. Doman, and each
of them singly, as his/her true and lawful attorney-in-fact and agent with full
power of substitution and resubstitution, for him/her and in his/her name, place
and stead, in any and all capacities, to sign any or all amendments (including
any pre-effective or post-effective amendments) to this registration statement
or any related registration statement that is to be effective upon filing
pursuant to Rule 462(b), and to file the same, with all exhibits thereto, and
other documents in connection therewith, with the Securities and Exchange
Commission, granting unto said attorney-in-fact and agent full power and
authority to do and perform each and every act and thing requisite and necessary
to be done in connection with the above premises, as fully to all intents and
purposes as he/she might or could do in person, hereby ratifying and confirming
all that said attorney-in-fact and agent or his substitute or substitutes, may
lawfully do or cause to be done by virtue thereof.
Pursuant to the requirements of the Securities Act of 1933, as amended,
this Registration Statement has been signed by the following persons in the
capacities and on the dates indicated:
/s/ D. Geoffrey Shulman Director, Chief Executive Officer and August 15, 2006
------------------------------------- Chairman of the Board (principal
D. Geoffrey Shulman, MD, FRCPC executive officer)
/s/ Richard C. Christopher* Vice President, Finance and Chief August 15, 2006
------------------------------------- Financial Officer (principal financial
Richard C. Christopher officer and principal accounting
officer)
/s/ John H. Abeles* Director August 15, 2006
-------------------------------------
John H. Abeles
/s/ David Bartash* Director August 15, 2006
-------------------------------------
David Bartash
/s/ Jay M. Haft* Vice-Chairman of the Board and Director August 15, 2006
-------------------------------------
Jay M. Haft, Esq.
/s/ Richard C. Lufkin* Director August 15, 2006
-------------------------------------
Richard C. Lufkin
/s/ Magnus Moliteus* Director August 15, 2006
-------------------------------------
Magnus Moliteus
/s/ Neal S. Penneys* Director August 15, 2006
-------------------------------------
Neal S. Penneys, MD, Ph.D.
* By: /s/ D. Geoffrey Shulman
-----------------------------------
D. Geoffrey Shulman, MD, FRCPC
Attorney-in-fact
INDEX TO EXHIBITS
(a) Exhibits:
(2.1) Merger Agreement dated December 30, 2005, as amended, by and among
DUSA, Sirius Laboratories, Inc. and certain shareholders of Sirius.
Filed with the Securities and Exchange Commission on March 10, 2006
as Exhibit 2(a.1) to the Company's Annual Report on Form 10-K for the
period ended December 31, 2005, and incorporated herein by reference.
(4.1) Common Stock specimen, filed as Exhibit 4(a) to the Registrant's Form
10-K for the fiscal year ended December 31, 2002, and is incorporated
herein by reference.
(4.2) Rights Agreement filed as Exhibit 4.0 to Registrant's Current Report
on Form 8-K dated September 27, 2002, filed October 11, 2002, and is
incorporated herein by reference.
(4.3) Rights Certificate relating to the rights granted to holders of
common stock under the Rights Agreement filed as Exhibit 4.0 to
Registrant's Current Report on Form 8-K, dated September 27, 2002,
filed October 11, 2002, and is incorporated herein by reference.
(4.4) Registration Rights Agreement by and among DUSA and certain
shareholders of Sirius dated March 10, 2006, filed as Exhibit 4.1 to
the Registrant's Current Report on Form 8-K dated March 14, 2006, and
incorporated herein by reference.
(5.1) Opinion of Reed Smith LLP.
(23.1) Consent of Deloitte & Touche LLP.
(23.2) Consent of Altschuler, Melvoin and Glasser LLP.
(23.3) Consent of Reed Smith LLP.
(24.1) Power of Attorney appointing D. Geoffrey Shulman, MD, FRCPC and
Robert F. Doman on original signature page.